https://www.dolcera.com/wiki/api.php?action=feedcontributions&user=Venkata.reddy&feedformat=atomDolceraWiki - User contributions [en]2024-03-28T20:41:05ZUser contributionsMediaWiki 1.24wmf12https://www.dolcera.com/wiki/index.php?title=Talk:China_ICU_Ventilator_Market&diff=10543Talk:China ICU Ventilator Market2012-06-18T12:42:00Z<p>Venkata.reddy: </p>
<hr />
<div>"There are three types of ventilators- ICU, transport, and home care ventilators. ICU ventilators have a share of 50 percent value-wise and 30 percent volume, transport ventilators have a share of 30 percent value-wise and 40 percent volume-wise, and home care ventilators have a share of 20 percent value-wise and 30 percent volume-wise."<br />
Source:[http://www.medicalbuyer.co.in/index.php?option=com_content&task=view&id=2652&Itemid=48 Interview with RP Singh, MD, Instromedix India Pvt. Ltd.]</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Review.png&diff=10542File:Review.png2012-05-29T13:38:05Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Strategy_options.png&diff=10541File:Strategy options.png2012-05-29T13:37:53Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Data_collaboration1.png&diff=10540File:Data collaboration1.png2012-05-29T13:37:30Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Cost_reduction.png&diff=10539File:Cost reduction.png2012-05-29T13:36:53Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Sales_plan.png&diff=10538File:Sales plan.png2012-05-29T13:36:15Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Customer_segments.png&diff=10537File:Customer segments.png2012-05-29T13:36:07Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Major_hospitals.png&diff=10536File:Major hospitals.png2012-05-29T13:35:58Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Institutional_challenges.png&diff=10535File:Institutional challenges.png2012-05-29T13:35:21Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Major_products_in_india.png&diff=10534File:Major products in india.png2012-05-29T13:35:02Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Medical_Tourism.png&diff=10533File:Medical Tourism.png2012-05-29T13:34:11Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Vijay_Dikshit&diff=10532Dr. Vijay Dikshit2012-05-29T13:33:12Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Vijay Dikshit''' <br/><br />
MBBS , M.S. (Surgery), M.Ch (Thoracic Surgery)<br/><br />
Speciality: Cardio Thoracic Surgery<br/><br />
at Apollo Hospitals<br />
==Areas of Specialization==<br />
• Cardio-Thoracic Surgery<br/><br />
• Open Heart Operations which include - Coronary Bypass Surgeries<br/><br />
• Heart Valve Surgeries including Valve Replacements & Valve Repair Operations<br/><br />
• Correction of Congenital Cardiac Defects<br/><br />
• Miscellaneous Cardiac Operations like Cardiac tumors, etc<br/><br />
==Awards and Recognitions==<br />
• FIE National Award in 1994 from Dr. Man Mohan Singh<br/><br />
• Ramakrishna Mission - for dedicated service to humanity<br/><br />
• Felicitated by Medtronic Inc. USA for achieving 5000 Open Heart Surgeries in year 2000<br/><br />
• Felicitated by Apollo Hospitals Chairman Dr. Pratap C Reddy for performing 10000 Open Heart surgeries at Apollo Group<br/><br />
==Achievements==<br />
• The experience of independently performing over 8000 Open Heart Operations together with the experience of over 6000 Open Heart Operations in association with Dr. Girinath at Apollo Hospitals, Madras gives him one of the largest experiences in Open Heart Surgery in India<br/><br />
• 1991 - 1993 performed 362 Consecutive Coronary Bypass Surgeries without any mortality or serious complication. A record performance of that time.<br/><br />
• Has the experience of highest number of Mitral Valve Replacement Operation with Complete Chordal Preservation & Artificial Chordal Reconstruction. This is one of the latest techniques of Mitral Valve surgery. Presented this work in the Annual Conference of Cardio Vascular and Thoracic Surgery held at Madras in February 2002.<br/><br />
• Performed first time in South India, the operation of Thoracoscopic Closure of Patient Ductus Arteriosus, on a six year old male child in 1996.<br/><br />
• One of the first users and now has the largest experience in using Stentless Bioprosthetic Valve Replacement Surgery for Aortic Valve disease in India. This is the state of the art Tissue Heart Valve not yet commonly used in India in other Cardiac surgery centres.<br/><br />
• Successfully performed an Emergency Cardiac Surgery on a 2 days old infant, suffering from severe complex Congenital Heart Disease. The child had the second corrective surgery at the age of 8 months and again at the age of 4 years for complete cardiac correction.<br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Sanjay_Gupta&diff=10531Dr. Sanjay Gupta2012-05-29T13:32:59Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Sanjay Gupta'''<br />
Departments: Cardiothoracic Surgery <br/><br />
<br />
==Introduction==<br />
• Dr. Sanjay Gupta is currently a Principal Consultant, Cardiothoracic and vascular surgery at Fortis Escort Heart Institute Okhla New Delhi and at Fortis flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi. <br/><br />
==Education==<br />
• He passed his MBBS (1986) and MS General Surgery (1991) from MLN Medical College, Allahabad, UP. <br/> <br />
• Subsequently he did his M.Ch. (Cardiovascular and thoracic surgery) from K.G's Medical College, Lucknow UP in 1994. <br/><br />
==Professional experience== <br />
• He worked at Batra Hospital and Medical Research Centre, New Delhi for eight years in the capacity of consultant cardiac surgeon under the great leadership of Dr. T.S. Mahant and played an important role in spearheading the programme of Cardiac Surgery to great height. <br/> <br />
• In 2003, he joined Narinder Mohan Hospital & Heart Centre, Mohan Nagar, Ghaziabad (UP) as H.O.D. and Chief Cardio-vascular and thoracic surgeon. <br/><br />
• He performed more than 500 surgeries over there, pertaining to all subspecialities of branch (viz coronary, congenital heart surgery, valvular heart surgery, all vascular and thoracic surgery). <br/><br />
• Subsequently he associated with Fortis Hospital, Noida, UP in later half of 2005, when hospital started its cardiac surgery programme. <br/><br />
• During his present appointment he was instrumental in the designing and commissioning of cardiac surgery department at Fortis Hospital, VasantKunj New Delhi . <br/><br />
• He was a key figure in launching the cardiac surgery programme at Fortis Hospital NOIDA ( 2005 ) , Fortis Hospital , Vasantkunj ( 2006 ) and Saraswati Heart Centre , Allahabad,UP ( 2007 ) <br/><br />
• Presently he is performing surgeries not only at Fortis Escorts Heart Institute ,Okhla & Fortis Hospital , Vasantkunj but also at related Hospitals and peripheral centres at Allahabad & GNRC Gauhati. <br/><br />
• He has done more than 5000 cardiac surgeries - more than 3500 CABG and other cardiac surgeries as MVR, AVR, DVR, Intra cardiac repair (for ASD, VSD , TOF etc.), pericardiectomy, PDA ligation, BT shunt, Glen’s shunt, aneurysm surgery etc. He has also done lots of vascular surgery. Now he is focusing mainly on Fortis Hospital, Vasant Kunj , New Delhi . <br/><br />
• Presently he is doing more than 50% cardiac surgeries with out any blood transfusion . <br/><br />
• He has developed expertise in performing cardiac surgery in renal dysfunction and chronic renal failure patient with near 0% mortality rate .He is performing nearly 100 % CABGs on beating heart only with out any conversion rate . <br/><br />
• He also has developed expertise in doing CABG in patients of Acute MI and cardiogenic shock . <br/><br />
==Fellowship==<br />
• He was honoured by awarding the fellowship of Indian Association of Cardio vascular & Thoracic Surgeons in 2007 . <br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Y._K._Mishra&diff=10530Dr. Y. K. Mishra2012-05-29T13:32:43Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Y. K. Mishra''' <br/><br />
Designation: Director at Fortis Escort Heart Institute<br/><br />
Department: Cardiothoracic Surgery <br/><br />
<br />
==Professional expertise==<br />
<br />
• Dr. Yugal K Mishra, Director – Cardiac Surgery at Fortis Escorts Heart Institute, is one of the pioneers of minimally invasive cardiac surgery in India. <br />
<br />
• Since joining Fortis Escorts Heart Institute in 1991, Dr. Mishra has been one of the key surgeons responsible for performing a significant portion of cardiac surgeries done at Fortis Escorts Heart Institute. He has operated over 7000 cardiovascular cases so far.<br />
<br />
• Dr. Mishra pioneered minimally invasive cardiac surgeries at Fortis Escorts Heart Institute including MIDCAB (Minimally Invasive Direct Coronary Artery Bypass Surgery), OPCAB (Off Pump Coronary Artery Bypass Surgery), and Port access approach for mitral valve surgery and ASD closure. Dr Mishra’s area of interest includes redo cardiac surgery and Robotic Cardiac Surgery, which he initiated in December 2002 at Escorts Heart Institute. He has performed more than 500 redo cases and over 350 robotic cardiac cases.<br />
<br />
==Education==<br />
<br />
• Born in 1954, Dr. Mishra completed his MBBS and MS from S.S Medical College in MP. He is a Ph.D in cardiovascular surgery from Bakulev Institute of Cardiovascular Surgery, Moscow, Russia and Fellow in cardiothoracic surgery at Thoracic Centre of University Hospital in Uppsala, Sweden.<br />
<br />
==Interests==<br />
<br />
• Beside Clinical work, Dr. Mishra is actively involved in research and has already published more than 70 scientific papers in national and international journals.<br />
<br />
• Dr. Mishra has the rare distinction of being a Director on the Board of Directors of International Society for Minimally Invasive Cardiac Surgery. He is the 4th Asian to be so honored and only the 2nd Indian to hold this distinction.</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Sunil_K_Kaushal&diff=10529Dr. Sunil K Kaushal2012-05-29T13:32:17Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Sunil K Kaushal''' <br/><br />
Departments: <br/><br />
• Cardiothoracic Surgery<br/><br />
• Pediatric & adult cardiac Surgery<br/><br />
• Pediatric Cardiothoracic Surgery <br/><br />
at Fortis Escort Heart Institute<br />
<br />
==Education==<br />
• Cardiac Surgical Training At AIIMS, New Delhi <br/><br />
• Overseas Pediatric cardiac surgical training include <br/><br />
• Clinical fellowship:Royal Children Hospital, Melbourne, Australia. <br/><br />
• Visiting fellowships:University of California, Sanfransisco & Cleveland Clinic Foundation USA Sick Children Hospital Toronto, Canada. <br/><br />
==Appointments and awards==<br />
• Committed Pediatric & Congenital Cardiac Surgeon in EHIRC since 1995. <br/><br />
• Actively involved in setting up of Pediatric & Congenital cardiac surgical unit in EHIRCL since its inception (1995). <br/><br />
• Numerous International and national Publications & Presentations. <br/><br />
• International member Society of Thoracic Surgeon USA. (www.ctsnet.org/home/skkaushal ) <br/><br />
• Life member of Indian Association of Cardiothoracic surgery. <br/><br />
• Teaching and Training post graduate & DNB trainees. <br/><br />
==Interests==<br />
Areas of special interest include:<br/><br />
• Neonatal & infant cardiac surgery<br/><br />
• Heart Valve repairs<br/><br />
• Pharmacomodulation in the ICU<br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Z._S._Meharwal&diff=10528Dr. Z. S. Meharwal2012-05-29T13:32:00Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Z. S. Meharwal''' <br/><br />
Designation: Director at Fortis Escort Heart Institute <br/><br />
Departments: Cardiothoracic Surgery <br/><br />
<br />
==Introduction==<br />
• Dr. Z. S. Meharwal, Director and Coordinator, Department of Cardiovascular Surgery at Fortis Escorts Heart Institute, is one the most renowned cardiac surgeons in India with over 7000 surgeries to his credit. <br/><br />
• Part of the founding team of Doctors at Fortis Escorts Heart Institute, Dr. Meharwal has been one of the core team of Doctors responsible for the global recognition earned by Fortis Escorts Heart Institute as a centre of excellence for clinical cardiac sciences. Every month, he performs an average of 60-70 open cardiac procedures including coronary artery bypass grafting, valve, combined valve and CABG, and aortic surgery. <br/><br />
==Education and awards==<br />
• Born in 1957, Dr. Meharwal completed his MBBS, MS and M.Ch from King George’s Medical College, Lucknow. <br/><br />
• He has an E.C.F.M.G Certificate from United States of America. <br/><br />
• He has been conferred with various awards including President’s award for his contribution in the field of cardiac surgery.<br/><br />
==Interest==<br />
• Dr. Meharwal’s areas of interest include Off pump coronary artery bypass surgery, CABG in patients with poor ventricular function, valve repair and replacement, surgery of ascending aortic aneurysm and dissections, peripheral vascular surgery and combined CABG and carotid endarterectomy. <br/> <br />
• He has to his credit a large number of research papers and studies extending the frontiers of clinical cardiac sciences in India. He has also authored sections in medical books on cardiology. <br/><br />
• He has worked as consultant cardiac surgeon at Prestigious King’s College Hospital in London where he has been actively involved in teaching undergraduate and postgraduate students. <br/><br />
• He is a keen trainer and has trained many cardiac surgeons in UK and in India. <br/><br />
• He is the Programme Coordinator of DNB (Diplomat National Board) Cardiothoracic Surgery at Escorts Heart Institute.<br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Surendra_Nath_Khanna&diff=10527Dr. Surendra Nath Khanna2012-05-29T13:31:47Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Surendra Nath Khanna''' <br/><br />
Designation: MS, MCh, FICS (USA) , FIACS, FAMS Senior Consultant at Fortis Escort Heart Institute <br/><br />
Departments: Cardiothoracic Surgery <br/><br />
Mobile No- 9810943535 <br/> <br />
Email: surendrank@hotmail.com <br/><br />
<br />
==Professional expertise==<br />
<br />
• Specialized in all types of adult cardiac surgical work. One of the leading and most experienced cardiac surgeon, specializing in beating heart surgeries and cardiac valvular surgery- mitral valve, aortic valve and double valve replacements; with vast experience in valve repairs, minimally invasive cardiac surgery aortic aneurysm surgery, and heart-failure surgery.<br/><br />
• Actively practising cardiac surgery with more then 6000 (Cardiac Surgeries) since last 25 years, at various prestigious institutes, which include – King George’s Medical College, Lucknow; Christian Medical College, Vellore; King Edward Memorial Hospital, Mumbai and Max Heart Institute, New Delhi and Fellow at San Raffaele Hospital, Milan with Prof. Ottavio Alfieri, pioneer in valve repair techniques. He had start, set up cardiac surgery center at Kanpur. At present, working as Senior Consultant, Cardiac Surgery, at Escorts Heart Institute, New Delhi. <br/><br />
• Involved in training the undergraduate and post-graduate students, and have trained many of the cardiac surgeons from UP, Punjab, Haryana, Bihar and Rajasthan with special interest in academic and research work, which include publications in various reputed international journals.<br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Ajay_Kaul&diff=10526Dr. Ajay Kaul2012-05-29T13:31:24Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Ajay Kaul''' <br/><br />
Designation: Director, Fortis Escort Heart Institute <br/><br />
Departments: Cardiothoracic Surgery <br/><br />
<br />
==Professional expertise==<br />
• Dr. Ajay Kaul has a vast surgical experience of over 10000 cardiac operations , which includes coronary bypass, valve replacement and repair, aneurysm surgery,& pediatric cardiac surgery. Fortis Escorts has installed a second latest Davinci Robot for coronary bypass surgery and valve surgery, with over 1000 cases operated. This is one of the few Centers in Asia where full spectrum of robotic heart operation are being performed.<br />
<br />
• He is one of the few surgeons who do total arterial coronary bypass grafting. With over 3000 operations performed he has one of the largest experienced of total arterial surgery in the country. Total arterial bypass is at present the best way to treat coronary artery disease (heart attack).<br />
<br />
==Past staff positions==<br />
<br />
Dr. Kaul has held prestigion positions like:<br />
<br />
• Sr. Cardiac Surgeon and unit head, Bombay Hospital.<br/><br />
• Visiting Professor, Institute of Medical Sciences, BHU, Varanasi. <br/><br />
• Guest Professor Hannover Medical School Hannover Germany. <br/><br />
• Associate Professor, Tilak Medical College and Sion Hospital, Mumbai. <br/><br />
• Director Cardiac surgery B.M. Birla Heart Research Centre Kolkata. <br/></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Naresh_Trehan&diff=10525Dr. Naresh Trehan2012-05-29T13:31:05Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr Naresh Trehan'''<br />
<br />
Currently Dr. Naresh Trehan is the Chairman and Managing Director of Medanta - a multi-super speaciality Institute in Gurgoan<br />
<br />
==Appointments==<br />
• CMD Global Health Private Limited (Medicity)<br />
<br />
• Senior Consultant Cardiovascular Surgery at Apollo Hospital, Sarita Vihar, New Delhi from June 1, 2007 till Dec 31st 2009.<br />
<br />
• Executive Director and Chief Cardiothoracic and Vascular Surgeon, Escorts Heart Institute and Research Centre, Okhla Road, New Delhi, from 1988 – 2007<br />
<br />
• Appointed as Personal Surgeon to the President of India with effect from June, 1991.<br />
<br />
• Appointed as Honorary Consultant to the Cromwell Hospital, London U.K., with effect from March, 1994.<br />
<br />
• Appointed as Honorary Visiting Professor, Cardiovascular Surgery, LPS Institute of Cardiology, Kanpur (U.P.) with effect from June, 1996.<br />
<br />
• Appointed as Honorary Consultant, Cardiothoracic Surgery, to the Armed Forces Medical Services, with effect from March, 1997.<br />
<br />
• Appointed as Honorary Visiting Professor of Surgery, Bangladesh Medical College, Dhaka with effect from April, 2000.<br />
<br />
==Past staff appointments==<br />
• Attending Cardiothoracic Surgeon, New York University Medical Center, New York, U.S.A., 1979-1988<br />
<br />
• Attending Cardiothoracic Surgeon and Consultant, Bellevue Hospital of the city of New York, U.S.A<br />
<br />
• Chief Thoracic and Cardiovascular Surgery, Veterans Administration Hospital (Manhattan), U.S.A<br />
<br />
• Attending Cardiothoracic Surgeon, New York Infirmary-Beekman Downtown Hospital, New York, U.S.A., 1979-1988<br />
<br />
• Attending Cardiothoracic Surgeon, St. Vincent's Hospital and Medical Center, New York, U.S.A., 1979-1988<br />
<br />
==Professional experience==<br />
<br />
• After training in general surgery and subsequently cardiac surgery at premier institutions in U.S. (NYU Medical Centre), held important academic and clinical positions at the New York University Medical Center, Bellevue Hospital of the city of New York and Veterans Administration Hospital (Manhattan), U.S.A. His pioneering work in the field of coronary artery bypass surgery was at the New York University Medical Centre, New York, USA.<br />
<br />
• In 1988, despite a successful career in United States he returned to India and started Escorts Heart Institute and Research Centre - a pioneering state-of-the-art heart institute in India. Within a short period this Centre became an important land mark the world over in cardiac surgery and cardiology having successfully performed over 48,000 open heart surgeries which includes surgeries of coronary artery, valves, carotid arteries, aortic aneurysm, cardiomyoplasty, cardiac arrhythmias, myocardial total arterial revascularization, transmyocardial laser revascularisation, least invasive coronary artery surgery on a beating heart, reduction ventriculoplasty (Batista Operation), heart port access surgery and robotically assisted cardiac surgery with excellent results. Some of these operations have been performed by Dr. Trehan for the first time in India.<br />
<br />
• Dr Trehan left Escorts in 2007 to give shape to his dream project Medanta - The Medicity, a multi super-specialty hospital located in Delhi’s NCR region, Gurgaon. Spread over 45 acres, Medanta is a 1500 bed hospital with 45 operating theatres which will cater to over 20 super-specialties. Medanta aims to match the standards of clinical care, research and education offered by the likes of Mayo/Harvard and Cleveland Clinics, while making treatments affordable.<br />
<br />
• Besides clinical work Dr Trehan has taken keen interest in training, education and research programmes. He is giving post doctoral training of international standard to 30 surgeons at a point of time, The training is of 3 years duration. Over 20 surgeons have already been trained so far. <br />
<br />
• Dr Trehan has also presented a number of scientific papers and chaired scientific sessions in national and international conferences in USA, UK, Japan, China, Israel and Far East countries.</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Ashok_Seth&diff=10524Dr. Ashok Seth2012-05-29T13:29:47Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Ashok Seth'''<br />
<br />
Designation: Chairman - Cardiac Sciences, Fortis Escorts Heart Institute<br />
<br />
Departments: Invasive Cardiology, Cardiology<br />
<br />
==Introduction==<br />
<br />
Dr. Seth has contributed extensively to the growth, development and scientific progress of Cardiology especially Interventional Cardiology in India and across the world.<br />
<br />
Over the past 20 years he has pioneered numerous angioplasty techniques for India and Asia Pacific region. His expertise, skills and his pioneering efforts in teaching and training in angioplasty have won him respect and accolades all across the world.<br />
<br />
He is perhaps one of the most recognized and respected Indian Cardiologist across the globe. His efforts have created a unique respect for India on the international sphere especially in the West.<br />
<br />
For his unique achievements and contributions he was honoured by the National award of ‘PADMA SHRI’ by the President of India in 2003.<br />
<br />
Dr. Seth is also founder advisory board member / governor to several prestigious international scientific bodies in the world including the Asia Pacific Society of Interventional Cardiologist and SAARC Cardiac Society and Society of Cardiovascular Angiographies and Interventions (USA).<br />
<br />
Dr. Ashok Seth has been highly decorated by the national academia and by citizens’ forums throughout the country and abroad.<br />
<br />
Dr. Seth was the first cardiologist in Asia Pacific region to perform Directional Atherectomy, Angioscopy, Stents, Thrombectomy devices & Drug Eluting Stents and use of Impella heart support device failing heart. He has performed one of the higest number of angiographies and angioplasties in the world – which is acknowledged by the ‘LIMCA ‘Book of Records.<br />
<br />
Dr. Seth was also instrumental in the core team which created the Escorts Heart Institute, New Delhi from its first day when he became the Head of Invasive and Interventional Cardiology on his return from England on 3rd October 1988. He was one of the key pillar to make it into one of the most famous landmark institutes in the World. He left the Escorts Heart Institute in Dec’04 to create a new standard in cardiac care in Max Heart & Vascular Institute.<br />
<br />
Dr. Seth has the unique honor to be invited to demonstrate and teach complex angioplasty techniques via the satellite transmission from New Delhi to the ‘Transcatheter Cardiovascular Therapeutics in 2003 & 2007’ Meeting in Washington DC (USA) and to EuroPCR in Paris in 2006 (from Bangkok) & in 2003 (from Chennai), which are the most important and biggest meetings of Interventional Cardiologists across the World. This is a unique prestige and privilege for India and a first for any Interventional Cardiologists in Asia. He has also done live transmissions of complex angioplasty techniques from India to international meetings in Singapore, Malaysia, Paris, China, Australia, Korea, Sri Lanka etc.<br />
<br />
Dr. Seth has been invited to lecture / demonstrate complex angioplasty techniques to more than 300 international courses & meetings across the globe.<br />
<br />
Dr. Seth has been highly acclaimed internationally for academics and research. He is the-<br />
*Associate Editor of International Journal of Cardiology<br />
*Member, Editorial Board<br />
**Journal American College of Cardiology – Cardiovascular Interventions<br />
**Catheterization and Cardiovascular Intervention<br />
**Euro Intervention.<br />
<br />
==Additional Professional Appointments==<br />
<br />
'''Honorary Professor of Cardiology'''<br />
<br />
*Gandhi Medical College, Bhopal (2000 onwards)<br />
<br />
*Medical College, Raipur (2001 onwards)<br />
<br />
*Medical College, Bilaspur (2001 onwards)<br />
<br />
*Padmashree Dr. D Y Patil University (2008 onwards)<br />
<br />
'''Honorary Professor of Cardiology'''<br />
<br />
*Bangladesh Medical College, Dhaka, Bangladesh, (1998 onwards)<br />
<br />
'''Honorary National Professor'''<br />
<br />
*Annual Course on Cardiovascular and Thoracic Surgery, Association of Cardiovascular and Thoracic Surgeons of India, (1996 onwards) “Dudley” Visiting Professor University of Birmingham, Department of Cardiovascular Medicine, Queen Elizabeth Hospital, Birmingham, U.K (1995)</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Dr._Vivek_Jawali&diff=10523Dr. Vivek Jawali2012-05-29T13:27:30Z<p>Venkata.reddy: </p>
<hr />
<div>'''Dr. Vivek Jawali''' <br />
<br />
M.S., MNAMS,M. Ch. (C.T Surg.), FIACS<br />
<br />
Chief Cardio–Thoracic & Vascular Surgeon, <br />
<br />
Fortis-Wockhardt Hospitals, Bangalore <br />
<br />
<br />
==Introduction==<br />
<br />
Dr. Jawali brings with himself a vast experience of performing more than eighteen thousand surgeries and has presented more than 100 scientific papers. He has also performed India’s first minimally invasive bypass surgery (MIDCAB), and also a minimally invasive valve replacement. He pioneered the movement of minimally invasive heart surgery in India. In 2004, he performed World’s first awake major OPEN HEART surgery (Aortic valve replacement with triple bypass), with patient fully awake, without ventilator even when the heart is stopped. He has eight international scientific publications to his credit on this issue.<br />
<br />
Dr. Jawali has demonstrated newer techniques of bypass surgery at live surgical workshops in India and abroad. Many cardiac surgeons and cardiac anaesthetists from all over the world visit to observe and learn the new techniques from him. He is actively involved in training the senior cadre of cardiac surgeons from china in the art of Off pump bypass surgery. <br />
<br />
==Surgical Expertise==<br />
<br />
• Off pump Coronary Artery Bypass surgery (OPCAB) <br />
<br />
• Minimally Invasive Direct Coronary Artery Bypass Surgery (MIDCAB) <br />
<br />
• CABG with Total Arterial Revascularisation <br />
<br />
• Off pump Total Arterial Revascularisation <br />
<br />
• Redo CABGs <br />
<br />
• Triple Valve Replacement <br />
<br />
• Mitral Valve Repair <br />
<br />
• Repair of LV Aneurysm + CABG <br />
<br />
• Grafting of Aortic Arch Aneurysm under profound Hypothermia and Total Circulatory Arrest <br />
<br />
• Aortic Root Replacement <br />
<br />
• Intracardiac repair of tricuspid atresia with TCPC <br />
<br />
==Fellowships and Surgical Observations Abroad==<br />
<br />
• With Dudley Johnson MD, St.Mary’s Hopital MILWAUKEE, USA (Redo CABG and Endarterectomy) <br />
<br />
• Mr. John Wright London Chest Hospital & The Princess Grace Hospital, London <br />
<br />
• Mr. Steven J.Westbay John Radcliff Hospital Oxford UK (Fast tracking) <br />
<br />
• Mr. Steven J.Philips, MD Mercy Hospital, Des Monies, USA (Primary CABG for Acute M.I) <br />
<br />
• Prof. Calafiore, University Hospital Chieti, Italy, (Total Arterial Revascularization, Warm Heart Surgery, MIDCAB, Skeletanisation of IMAS.) <br />
<br />
• Dr. Erick Jansen University Hospital Utrecht, Netherland, (CABG on Beating Heart with Octopus Tissue stabilisation & skeletonisation of IAMS) <br />
<br />
• Dr. Urbon Lonn, University Hospital Linchoping, Sweden.</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Procedure_charges.png&diff=10522File:Procedure charges.png2012-05-29T13:26:13Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Valve_Replacements.png&diff=10521File:Valve Replacements.png2012-05-29T13:24:01Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Key_Hospitals.png&diff=10520File:Key Hospitals.png2012-05-29T13:21:36Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Distributors_%26_Stockists.png&diff=10519File:Distributors & Stockists.png2012-05-29T13:20:41Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Sales_Force_Structure-Heart_Valves.png&diff=10518File:Sales Force Structure-Heart Valves.png2012-05-29T13:20:37Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Value_Chain-_Heart_Valves.png&diff=10517File:Value Chain- Heart Valves.png2012-05-29T13:20:26Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Artifical_Aortic_Valve.jpg&diff=10516File:Artifical Aortic Valve.jpg2012-05-29T13:11:56Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Heart_Valve_Market.png&diff=10515File:Heart Valve Market.png2012-05-29T13:11:07Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Level2.png&diff=10514File:Level2.png2012-05-29T13:10:29Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Level1.png&diff=10513File:Level1.png2012-05-29T13:09:58Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Global_market.png&diff=10512File:Global market.png2012-05-29T13:09:28Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Ross_Procedure.gif&diff=10511File:Ross Procedure.gif2012-05-29T13:06:03Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Procedure_Segmentation.png&diff=10510File:Procedure Segmentation.png2012-05-29T13:05:11Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Allograft_Valves.png&diff=10509File:Allograft Valves.png2012-05-29T13:02:19Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Homograft_Valves.png&diff=10508File:Homograft Valves.png2012-05-29T13:00:07Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Mechanical_Valve.png&diff=10507File:Mechanical Valve.png2012-05-29T12:57:24Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Tissue_Valve.png&diff=10506File:Tissue Valve.png2012-05-29T12:56:44Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Heart_Valve.gif&diff=10505File:Heart Valve.gif2012-05-29T12:56:05Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Strategic_Insights:Heart_Valve_Replacement_Market_-_India&diff=10504Strategic Insights:Heart Valve Replacement Market - India2012-05-29T12:55:21Z<p>Venkata.reddy: </p>
<hr />
<div>=Introduction=<br />
For blood to go in only one direction, forward, it must pass through the heart valves, which function as one-way doors, opening and shutting with each beat of the heart. Just as there are four chambers to the heart, there are four heart valves. Blood must pass through one of these valves each time it leaves a chamber.<br><br />
The Four Heart Valves:<br />
#''' Tricuspid''': The tricuspid valve is named because it has three leaflets. It is located between the right atrium and right ventricle.<br />
#'''Pulmonary''': The pulmonary valve is named because it is located below the pulmonary artery, between the right ventricle and the pulmonary artery.<br />
#'''Mitral''': The mitral valve is named because it looks like an upside down bishop's hat or mitre. It is the only heart valve with two leafets; all of the others have three. It is located between the left atrium and left ventricle.<br />
#'''Aortic''': The aortic valve is named because it is located below the aorta, between the left ventricle and aorta. <br />
<br>[[Image:Heart Valve.gif|thumb|center|600px|A superior view of the heart showing the four valves. The aortic valve is most commonly replaced.]]<br><br />
The two valves located between the atria and ventricles, the tricuspid and mitral valves, are known as atrioventricular valves. The two other valves, the pulmonary and aortic, are sometimes called semilunar valves, because each of those valves has leaflets that are shaped like half-moons.<br />
<br><br />
<br />
Sources:[http://www.cfhalliance.org/allianceheart/HeartValve-Info.html Alliance Heart Institute],[http://www.pages.drexel.edu/~nag38/index.html Drexel.edu]<br />
==Types of heart valves==<br />
When someone has to have a heart valve replaced, there are a few things that are done to determine what type of valve the patient will recieve. The patient could recieve one of the following valves: mechanical valves, tissue valves, homograft valves, or allograft valves. These all have there advantages and disadvantages.<br />
<br><br />
<br />
'''Tissue Valves''': A tissue valve is another field of valves that are taken from an animal and put into human hearts. These kinds of valves are chemically treated for safety and are prepared for the human heart (St. Jude Medical, Inc., 2007). Since these valves are weak, they are reinforced with a frame or stent to make them stronger, and to support the valve. The valves that aren’t reinforced are called stentless valves (St. Jude Medical, Inc., 2007).<br />
These types of valves aren’t a good choice for younger patients because they wear out quickly. They wear out because they stretch when the demand of blood flow increases (Aortic valve replacement, 2007). Another reason as to why they aren’t used often is because when these valves wear out, the patient will have to under go another operation to get a new valve implanted to replace the previous one. These valves last, on average, 10-15 years in the less active patients such as the elderly, while in the younger and more active patients, they wear out a lot faster (Aortic valve replacement, 2007).<br><br />
[[Image:Tissue Valve.png|thumb|center|600px|Tissue Valve]]<br />
'''Mechanical Valves''': Mechanical valves are designed to mimic a real heart valve (St. Jude Medical, Inc., 2007) and to outlast the patient (Aortic valve replacement, 2007). All versions have a ring to support the leaflets (flaps) like a natural valve and has a thin polyester mesh cuff on the circumference of the valve for easier implantation.<br />
This is for easier implantation (St. Jude Medical, Inc., 2007). These valves are not controlled electronically but naturally. As the heart beats, the mechanical valve opens and closes (St. Jude Medical, Inc., 2007). These valves have been proven to last several hundred years by being stress-tested (Aortic valve replacement, 2007).<br />
[[Image:Mechanical Valve.png|thumb|center|600px|Mechanical Valve]]<br><br />
<br />
'''Homograft Valves''': The third type of valve is a homograft valve. This a valve that is taken form a human donor (St. Jude Medical, Inc., 2007; Encyclopedia of Medicine, 2006).These donor valves are only given to patients who will deteriorate rapidly because of a narrowing of the passageway between the aorta and that left ventricle (Encyclopedia of Medicine, 2006)<br />
This type of valve is better for pregnant women and children (St. Jude Medical, Inc., 2007. Unlike most valves, this type of valve does not require anticoagulation therapy over a long time (long-term) (St. Jude Medical, Inc., 2007).Durability of a homograft is approximately the same as a tissue valves (Aortic valve replacement, 2007).These valves are sometime, but rarely, taking from the patients own pulmonic valve (Encyclopedia of Medicine, 2006).<br />
[[Image:Homograft Valves.png|thumb|center|600px|Homograft Valve]]<br><br />
<br />
'''Allograft Valves''':The fourth type of valve is an allograft valve. These valves are usually taken from pig's aortic valve (Encyclopedia of Medicine, 2006). They are chemically treated before they are put into a human heart. The life span of one of these valves is about 7-15 years, depending of the patient (Encyclopedia of Medicine, 2006). Because of the short life span of this valve, it is generally given to the older patients (Encyclopedia of Medicine, 2006).<br />
[[Image:Allograft Valves.png|thumb|center|600px|Allograft Valve]]<br><br />
<br />
Source:[http://www.odec.ca/projects/2007/schw7e2/Types_of_valves.html odec.ca]<br />
<br />
==Disorders treated by heart valves==<br />
#'''Valvular Stenosis:'''This occurs when a valve opening is smaller than normal due to stiff or fused leaflets. The narrowed opening may make the heart work very hard to pump blood through it. This can lead to heart failure and other symptoms (see below). All four valves can be stenotic (hardened, restricting blood flow); the conditions are called tricuspid stenosis, pulmonic stenosis, mitral stenosis or aortic stenosis.<br />
#'''Valvular Regurgitation:'''This occurs when a valve does not close tightly. If the valves do not seal, some blood will leak backwards across the valve. As the leak worsens, the heart has to work harder to make up for the leaky valve, and less blood may flow to the rest of the body. Depending on which valve is affected, the conditioned is called tricuspid regurgitation, pulmonary regurgitation, mitral regurgitation or aortic regurgitation.<br />
Source:[http://www.medicinenet.com/heart_valve_disease/article.htm#toca Medicinenet]<br />
<br />
==Heart valve procedures==<br />
===Procedure of Heart Valve Surgery===<br />
<br />
Heart valve surgery means repair or replacement of the diseased valves. In the surgery, some valves are repaired or mended to do its work properly. Replacement means removal of the diseased valves by a new valve. The procedures of heart valve surgery are :<br />
<br />
#Valve Repairing : In the valve repair surgery, a ring is sewn around the opening of the valve to make tighter. The surgeons may cut the other parts or may separate and shorten it to help the valve open and close right.<br />
#Valve Replacement : Sometimes by mending the valves, it is not possible to cure the unhealthy valve, and then replacement is required to get back its normal function. A prosthetic valve is used to replace. There are two types of prosthetic valves. <br />
##Mechanical valves : These types of valves are made from man-made materials. While heart surgeons’ use this valve, lifetime therapy with an anticoagulant is prescribed to the patient.<br />
##Biological (tissue) valves : The surgeons take biological valves from pig, cow or human donors. The longevity of biological valves is less than the mechanical valves.<br />
<br />
Source:[http://www.indian-medical-center.com/heart-valve-surgery.html Indian-medical-center]<br />
<br />
[[Image:Procedure Segmentation.png|thumb|center|700px|Procedure Segmentation]]<br />
===Heart valve procedures by technique===<br />
'''Transcatheter Aortic Valve Implantation (TAVI)'''<br />
<br />
'''Description''' This technique involves insertion of a miniaturized valve through a catheter from the groin. The deployed valve is later inflated at the site of the aortic valve. The entire procedure is conducted under general anesthesia and takes about an hour. It is a non-surgical procedure. In TAVI inner organs are accessed via needle-puncture of the skin, rather than by using a scalpel.<br />
<br />
'''Procedures in India''' TAVI is still in nascent trial stage in India. In mid of March, a team of doctors at Delhi's Fortis Hospital headed by Dr Ashok Seth operated three patients using TAVI.<br />
<br />
'''Cost of surgery in India''' The cost of procedure is 29,350 USD which include the cost of valve 21,500 USD (approx).<br />
<br />
'''Prevalence''' After the age of 75 years, 5% population is at the risk of developing a problem in their heart valve, out of which 35% are not suitable for surgery. If not treated, 50% of them will not survive for more than two years.<br />
<br />
Source:[http://articles.timesofindia.indiatimes.com/2012-03-28/lucknow/31249104_1_transcatheter-aortic-valve-implantation-open-heart-heart-surgery Indiatimes]<br />
<br><br />
<br />
'''Ross Procedure'''<br />
<br />
The Ross Procedure is a type of specialized aortic valve surgery where the patient's diseased aortic valve is replaced with his or her own pulmonary valve. The pulmonary valve is then replaced with cryopreserved cadaveric pulmonary valve. In children and young adults, or older particularly active patients, this procedure offers several advantages over traditional aortic valve replacement with manufactured prostheses.<br />
<br><br />
Source:[http://www.cts.usc.edu/rossprocedure.html University of Southern California]<br />
<br />
[[Image:Ross Procedure.gif|center|thumb|700px|Source: [http://www.heart-valve-surgery.com/heart-surgery-blog/2009/09/13/annual-yearly-ross-procedures-aortic/ heart-valve-surgery]]]<br />
<br />
<br><br />
<br />
*[http://www.heart-valve-surgery.com/heart-surgery-blog/2009/09/13/annual-yearly-ross-procedures-aortic/ 1,500] Ross procedures are performed annually on a global basis. In US, this number is around 1,000.<br />
<br />
=Current Worldwide Market=<br />
==Market size==<br />
[[Image:global market.png|thumb|center|700px|Source: [http://www.researchandmarkets.com/reportinfo.asp?report_id=1199695&t=e TechNavio Report]]]<br />
<br />
==Trends==<br />
*Aortic Valve segment represents 55% of the overall market. However, with 35-50% of patients suffering from severe aortic stenosis considered at high risk for surgery, the current number of patients eligible for TAVI procedures is 200,000 worldwide.<br />
*The TAVI segment thus represents a $2B market opportunity. According to various sources, this market size will be reached in 2014.<br />
*The Brazilian, Russian, Indian, and Chinese (BRIC) heart valve device market—comprising sales of heart valve replacement (mechanical, tissue, and transcatheter aortic valve replacement [TAVR]) and heart valve repair (annuloplasty) devices—was valued at nearly $180 million in 2011 and will expand through 2016, driven primarily by rising heart valve procedure volumes.<br />
*Rapid economic growth and an aging population, which are increasing both the prevalence of valvular heart disease and patients’ ability to pay for treatment, constitute the primary drivers of growth in the BRIC heart valve device market.<br />
*The patient population will also expand as government funding for health care infrastructure improves the accessibility and affordability of the procedures for patients across all BRIC nations.<br />
*Rising penetration of tissue heart valves will contribute further to market growth due to the premium price of these devices compared to mechanical heart valves.<br><br />
Sources:[http://mrg.net/Products-and-Services/Syndicated-Report.aspx?r=RPBC12HV12 MRG Report],[http://www.symetis.com/pages.php?rubID=12&lan=en Symetis Website]<br />
<br />
==Recent Approvals==<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Date'''</font><br />
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Company'''</font><br />
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Country'''</font><br />
|align = "center" bgcolor = "#4F81BD" width="60%"|<font color="#FFFFFF">'''Product Approved'''</font><br />
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Source'''</font><br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Apr 2012<br />
|align = "center" bgcolor = "#DBE5F1"|St. Jude Medical<br />
|align = "center" bgcolor = "#DBE5F1"|Japan<br />
|align = "center" bgcolor = "#DBE5F1"|The new Trifecta aortic stented, pericardial tissue valve has been implanted in procedures atOsaka University Hospital and Saitama Medical University International Medical Center<br />
|align = "center" bgcolor = "#DBE5F1"|[http://medcitynews.com/2012/04/st-jude-medical-gets-approval-to-sell-smaller-heart-valve-in-japan/ Medcity News]<br />
|-<br />
|align = "center"|Nov 2011<br />
|align = "center"|Edward Lifesciences<br />
|align = "center"|US<br />
|align = "center"|The Sapien Transcatheter Heart Valve will provide some people with this condition who can<nowiki>’</nowiki>t undergo open heart surgery with the option of valve replacement<br />
|align = "center"|[http://online.wsj.com/article/SB10001424052970203804204577014790010981970.html Wallstreet Journal]<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|July 2011<br />
|align = "center" bgcolor = "#DBE5F1"|Sorin Group<br />
|align = "center" bgcolor = "#DBE5F1"|Europe<br />
|align = "center" bgcolor = "#DBE5F1"|Mitroflow Aortic Pericardial Heart Valve<br />
|align = "center" bgcolor = "#DBE5F1"|[http://www.sorin.com/node/2677 Sorin]<br />
|-<br />
|align = "center"|Jan 2011<br />
|align = "center"|Sorin Group<br />
|align = "center"|Europe<br />
|align = "center"|Innovative Self-Anchoring Aortic Heart Valve, Perceval™ S<br />
|align = "center"|[http://www.sorin.com/medical-professionals/heart-valves/spotlight/news-2 Sorin]<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|May 2010<br />
|align = "center" bgcolor = "#DBE5F1"|CryoLife<br />
|align = "center" bgcolor = "#DBE5F1"|US<br />
|align = "center" bgcolor = "#DBE5F1"|Cryovalve SG Pulmonary Human Heart Valve (and Conduit)<br />
|align = "center" bgcolor = "#DBE5F1"|[http://www.accessdata.fda.gov/cdrh_docs/pdf9/K092021.pdf FDA]<br />
|-<br />
|}<br />
<br />
=Market in India=<br />
==Strategic Outlook==<br />
'''Level 1'''<br />
[[Image:Level1.png|thumb|center|600px|Dolcera Analysis]]<br />
'''Level 2'''<br />
[[Image:Level2.png|thumb|center|600px|Dolcera Analysis]]<br />
<br />
==Overview of market==<br />
===Current size===<br />
*The Indian market for heart valves was about 30,000 a year and a sizeable portion of that is being met by the TTK-Chitra valves. <br />
Source:Senior Executive at TTK Chitra [http://www.thehindu.com/opinion/op-ed/article69694.ece Hindu Article]<br />
[[Image:Heart Valve Market.png|thumb|center|600px|Source:Interviews with experts in the field]]<br />
<br />
<br />
<br />
==Regulatory landscape==<br />
===Overview===<br />
*Indian government is working on a comprehensive regulatory framework for the medical device sector because it has lacked a formal regulatory system for many years. Medical devices are currently either regulated as drugs or simply left unregulated.<br />
*In June 2009, the Drug Consultative Committee (DCC) and the Drug Technical Advisory Board (DTAB) approved new formal regulations for India's medical devices sector. The Health Ministry is set to issue the notification of these new regulations in the near future.<br />
<br />
According to the final draft of the newly proposed [http://cdsco.nic.in/Medical_Devices_Guidelines.pdf regulations], all medical devices have been broadly classified into the following categories:<br />
<br />
*Class A Devices: Low risk devices that include gloves and operating room utensils;<br />
*Class B Devices: Low to medium risk devices such as needles, surgical knives, and syringes;<br />
*Class C Devices: Moderate to high risk devices such as radiation equipment and heart–lung machines<br />
*Class D Devices: Very high risk and life supporting devices such as implantable pacemakers and defibrillators.<br />
<br />
===Recent approvals===<br />
Heart Valves notified as “drugs”: As per the notice dated 16/May/2005 from The Ministry of Health and Family Welfare, Govt. of India has notified Heart Valve devices to be considered as drugs under Section 3, Clause (b) . Sub clause (iv) of the Drugs and Cosmetics Act, notification number s.o.1468 (E).<br />
CDSCO: Medicines in India are regulated by CDSCO - Central Drugs Standard Control Organization. Under Ministry of Health and Family Welfare. Headed by Directorate General of Health Services CDSCO regulates the Pharmaceutical Products through DCGI - Drugs Controller General of India at Chair.<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|colspan = "7"|Registration Certificates issued for the Heart Valves along with their manufacturing sites and Indian Authorized agents in since 2010<br><br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|'''Date''' <br />
|align = "center" bgcolor = "#C5D9F1"|'''Name of Indian Agent'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Name of Manufacturer'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Name of the Device'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''File No.'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''R. C. No.'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Validity of the Registration Certificate'''<br />
|-<br />
| Jan. 2012 to Feb 2012<br />
|M/s. St. Jude Medical India Private Limited, Plot No. 18 & 19 Laxminagar, behind TB Hospital, Hyderabad-500038<br />
|M/s. St. Jude Medical Puerto Rico LLC, Lot 20-B, St. Cagaus Puerto Rico 00725<br />
|1. St. Jude Medical Mechanical Heart Valve 2.SJM Master Series (Rotatable)-Aortic <nowiki>+</nowiki> 9<br />
|31-28-MD/2006-DC (Re-Reg. 2_<br />
|MD-28<br />
|30-06-2015<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s India Medtronic Pvt. Ltd., 1241, Solitaire Corporate Park, Building Number 12, 4th Floor, Anheri-Ghatkopar Link Road, Andheri (E), Mumbai- 400094<br />
|M/s Medtronic Inc., 710 Medtronic Parkway N. E. Minneapolis MN 55432 USA having manufacturing premises at M/s Medtronic ATS Medical Inc., 3905 Annapolis Lane, Suite 105 Minneapolis, MN – 5547, USA<br />
|2. Open Pivot Aortic Valved Graft (AVG)<br />
|31-892-MD/2010-DC<br />
|MD-893<br />
|31-12-2014<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s Edward Lifesciences (India) Pvt. Ltd., E.F. 201-204, Remi Biz Court, Plot No. 9, Off Veera Desai Road, Andheri West, Mumbai- 400058<br />
|M/s Edward Lifesciences LLC, One Edwards Way, Irvine CA, USA 92614-5686<br />
|1. Carpentier-Edwards Bioprosthetic Valved Conduit<br />
|31-93-MD/2006-DC (Re-Registration 2010) (End. 1)<br />
|MD- 93<br />
|31-01-2013<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s Edward Lifesciences (India) Pvt. Ltd., E.F. 201-204, Remi Biz Court, Plot No. 9, Off Veera Desai Road, Andheri West, Mumbai- 400059<br />
|M/s Edward Lifesciences LLC, One Edwards Way, Irvine CA, USA 92614-5687<br />
|2. Edwards MC Tricuspid Annuloplasty System<br />
|31-93-MD/2006-DC (Re-Registration 2010) (End. 1)<br />
|MD- 94<br />
|31-01-2014<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s India Medtronic Pvt. Ltd., 1241, Solitaire Corporate Park, Building Number 12, 4th Floor, Anheri-Ghatkopar Link Road, Andheri (E), Mumbai- 400093<br />
|M/s Medtronic Inc., 710 Medtronic Parkway N. E. Minneapolis MN 55432 USA having manufacturing premises at M/s Medtronic Mexico S. de R.L de C.V. Avenida paseo del Cucapah 10510, Parque Industrial EI Lago, Tijuana, B.C. 22570<nowiki><</nowiki> Mexico<br />
|1. Sprinter rapid Exchange Balloon Dilatation Catheter<br />
|31-381-MD/2007-DC (Re-Reg. 2010)<br />
|MD-381<br />
|14-02-2014<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s India Medtronic Pvt. Ltd., 1241, Solitaire Corporate Park, Building Number 12, 4th Floor, Anheri-Ghatkopar Link Road, Andheri (E), Mumbai- 400094<br />
|M/s Medtronic Inc., 710 Medtronic Parkway N. E. Minneapolis MN 55432 USA having manufacturing premises at M/s Medtronic Mexico S. de R.L de C.V. Avenida paseo del Cucapah 10510, Parque Industrial EI Lago, Tijuana, B.C. 22570<nowiki><</nowiki> Mexico<br />
|2. Sprinter legent RX Balloon Dilatation Catheter<br />
|31-381-MD/2007-DC (Re-Reg. 2010)<br />
|MD-382<br />
|14-02-2015<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s India Medtronic Pvt. Ltd., 1241, Solitaire Corporate Park, Building Number 12, 4th Floor, Anheri-Ghatkopar Link Road, Andheri (E), Mumbai- 400095<br />
|M/s Medtronic Inc., 710 Medtronic Parkway N. E. Minneapolis MN 55432 USA having manufacturing premises at M/s Medtronic Mexico S. de R.L de C.V. Avenida paseo del Cucapah 10510, Parque Industrial EI Lago, Tijuana, B.C. 22570<nowiki><</nowiki> Mexico<br />
|3. Melody Transcatheter Pulmonary Valve<br />
|31-381-MD/2007-DC (Re-Reg. 2010)<br />
|MD-383<br />
|14-02-2016<br />
|-<br />
|Jan. 2011 to 20th December 2011<br />
|M/s. St. Jude Medical India Private Limited, A & B, 2nd Floor, Brij Tarang, Greenland, Begumpet, Hyderabad-500016<br />
|M/s. St. Jude Medical Cardiology Division Inc, DBA 177 County Rod, B East St. Paul, MN 55117, USA<br />
|Trifecta Valve Aortic (19mm-27mm)<br />
|31-26-MD/2006-DC (Re-Reg. 2009 (End 02)<br />
|MD-26<br />
|30-06-2012<br />
|-<br />
|}<br />
<br />
==Reimbursement landscape==<br />
<br />
#Aarogyasri in Andhra Pradesh State<br />
#Jeevandayi Yojana in Maharashtra State<br />
#Kalignar's Insurance Scheme<br />
<br />
===[https://www.aarogyasri.org/ASRI/index.jsp Aarogyasri]===<br />
*It is a flagship scheme of all health initiatives of the State Government with a mission to provide quality healthcare to the poor. The aim of the Government is to achieve "Health for All" in Andhra Pradesh state.<br />
*In 2007, the Andhra Pradesh government launched ’Aarogyasri’, a community health insurance scheme for the poor (Under this scheme, the hospitals received a fixed amount for valve replacement operations).<br />
[http://ibnlive.in.com/generalnewsfeed/news/entire-maha-to-be-covered-under-rajiv-gandhi-health-scheme/982401.html Jeevandayi Yojana]<br />
*The Maharashtra state government provides financial assistance to people falling in the below poverty line (BPL) category for treatment of various diseases.<br />
*Under this scheme, doctors perform major operations within an upper limit of Rs 1.5 lakh.<br />
===Kalignar's Insurance Scheme===<br />
*Tamil Nadu launched the “Kalaignar’s Insurance Scheme for Life Saving Treatments” for families with an annual income less than Rs. 72,000.<br />
*Each family will enjoys benefits up to Rs. 1 lakh for certain procedures in private hospitals and pay wards in government hospitals.<br />
*Private insurance company Star Insurance, contracted to implement the scheme, has entered into contracts with a number of hospitals in private health care centres and hospitals throughout the State. There will be a minimum of six hospitals in each district and 15 hospitals in the major cities. The government will pay the premium of Rs. 500 per annum. A total of Rs. 517.30 crore is the allotment for the current financial year.<br />
<br />
===Reimbursement rates===<br />
In India, the reimbursement rate for procedures varies from one insurance company to another. Typically, Heart Valve Replacement procedure falls under major illness category. The amount of reimbursement is typically dependent on the sum assured.<br />
<br />
* '''United India Assurance - '''Pre and Post Hospitalisation expenses payable in respect of any illness shall be the actual expenses incurred subject to a maximum of '''10% of the Sum Insured''' whichever is less. For major illnesses, the expenses are settled on a co-pay of 80:20 ratio. The co-pay of 20% will be charged as a total package applicable on the admissible claim amount.<br />
* '''Life Insurance Corporation - '''For major cardiovascular surgical procedures like Valve replacement surgery, open heart surgery for vale repair and heart by-pass surgery, up to 100% of sum assured could be claimed.<br />
* '''ICICI Lombard Insurance - '''For critical illnesses like Coronary artery bypass graft surgery and Heart valve replacement surgery, the insured is entitled to the lumpsum benefit of the 100% of the sum insured for. The insurance sum may vary between $12,000 - $24,000.<br />
* The reimbursement for medical devices like valve, stent, pacemaker etc. are evaluated on a case-to-case basis.<br />
<br />
Source: [http://www.uiic.co.in/pdf/policydocs/health/SENIOR_CITIZEN_POLICY_PROSPECTUS.pdf UIA], [http://www.licindia.in/images/health_plus_brochure.pdf LIC], [http://www.nriol.com/indianinsurance/icici-lombard-insurance/critical-care-insurance.asp ICICI Lombard]<br />
<br><br />
<br />
==Technology landscape==<br />
An artificial heart valve is a device implanted in the heart of a patient with heart valvular disease. Natural heart valves become dysfunctional for a variety of pathological causes. When one of the four heart valves malfunctions, the medical choice may be to replace the natural valve with an artificial valve.<br />
<br />
[[Image:Artifical Aortic Valve.jpg|left|thumb|Source:[http://medgadget.com/2010/09/transcatheter_aorticvalve_implantation_tavi_reduces_mortality_rate_compared_to_standard_therapy.html Artificial Aortic Valve]]]<br />
<br />
There are two main types of artificial heart valves:<br />
<br />
* '''Mechanical valves''' - prosthetics designed to replicate the function of the natural valves of the human heart.<br />
<br />
* '''Biological valves''' - valves of animals, like pigs, which undergo several chemical procedures in order to make them suitable for implantation in the human heart.<br />
<br />
One of the greatest biomedical engineering challenges today is to develop an implantable device that resists the natural conditions to which heart valves are subjected, without eliciting host reactions that would impair their function. Currently, no artificial heart valve device, either mechanical or tissue-derived, fulfills the required prerequisites for an ideal heart valve.<br />
<br />
<br><br />
<br />
'''Regenerative medicine approaches to heart valve replacement:'''<br />
<br />
Regenerative medicine is based on principle of using the patient’s own cells and extracellular matrix components to restore or replace tissues and organs that have failed. Modern approaches to heart valve regenerative medicine include several research methodologies with the most intensely researched approaches being:<br />
<br />
* the use of decellularized tissues as scaffolds for in situ regeneration<br />
<br />
* construction of tissue equivalents in the laboratory before implantation, and<br />
<br />
* use of scaffolds preseeded with stem cells.<br />
<br />
The regenerative medicine approach is however still in its nascent stages.<br />
<br />
<br />
'''Future and perspesctives:'''<br />
<br />
Effective treatments of valvular disease continues to present multiple challenges. The exciting<br />
lines of investigation in this area are:<br />
<br />
* Finding causes and developing nonsurgical therapy approaches for valvular disease<br />
<br />
* Improvement of current artificial devices<br />
<br />
* Regenerative medicine approaches<br />
<br><br />
<br />
=====Ross procedure=====<br />
<br />
*This technique involves replacing diseased aortic and mitral vales with the patient's own pulmonary valve and valves collected from cadavers replace the pulmonary valve. <br />
<br />
Arkalgud Sampath Kumar- [http://askheartsurgeon.com/about.html Biography]<br />
<br />
=====Percutaneous Transcatheter Aortic Valve Implantation (TAVI)=====<br />
<br />
*In TAVI, a replacement valve is passed through a hole in the groin by a puncture of the femoral artery and advanced up to the ascending aorta of the patient. It substitutes for a more invasive procedure in which the chest is opened. The survival is equivalent, but the risk of stroke is higher.<br />
<br />
<br />
[http://www.4-traders.com/FORTIS-HEALTHCARE-INDIA-L-9059727/news/FORTIS-HEALTHCARE-INDIA-LTD-India-s-First-Successful-Percutaneous-TAVI-Performed-At-Fortis-Escorts-14219316/ Dr. Ashok Seth], Fortis Healthcare, Delhi<br />
<br><br />
<br />
<br />
=====Transcatheter Pulmonary Valve (TPV) Therapy=====<br />
<br />
<br />
*'''Transcatheter pulmonary valve therapy''' or '''Percutaneous pulmonary valve implantation (PPVI)''' treats narrowed or leaking pulmonary valve conduits without open-heart surgery.<br />
*With transcatheter pulmonary valve therapy, a catheter (a thin, hollow tube) holding an artificial heart valve is inserted into a vein in the leg and guided up to the heart. The heart valve is attached to a wire frame that expands with the help of balloons to deliver the valve. Once the new heart valve is in position, it begins to work immediately.<br />
<br />
Source:[http://www.medtronic.com/patients/pulmonary-valve-disease/therapy/what-is-it/index.htm Medtronic]<br />
<br />
==Distribution landscape==<br />
'''Value Chain- Heart Valves'''<br />
<br />
[[Image:Value Chain- Heart Valves.png|thumb|center|600px|Source:Interviews with experts in the field]]<br />
<br />
'''Sales Force Structure'''<br />
<br />
[[Image:Sales Force Structure-Heart Valves.png|thumb|center|600px|Source:Interviews with experts in the field]]<br />
<br />
'''Distributors & Stockists'''<br />
<br />
[[Image:Distributors & Stockists.png|thumb|center|600px|Source:Interviews with experts in the field]]<br />
<br />
'''Distribution Channel:''' <br />
*Distribution channel generally consists of the company, distributor & Hospital while Doctors being the key influencer regarding which valves should be procured. Patients are rarely aware of brands generally go by the Doctors choice which is conjunction with their paying capacity & need of the surgery.<br><br />
*Big private chain of Hospitals sometimes bypass distributor and directly deal with manufacturing company. Discussed in detail in pricing section.<br><br />
*Distributors are majorly concentrated in metropolitans like New Delhi, Chennai, Mumbai, ,Kolkata ,Bangalore, Hyderabad etc. and also cater to regions nearby.<br><br />
*Commercial activities are done by stockist while companies sales force provide technical support to doctors , addresses the all issues faced to streamline the process & take feedback at every level in supply chain.<br><br />
<br />
'''Distribution channel at government hospitals:'''<br />
*Hospital floats a tender on basis of their requirement. The stockist quote price for 6 months/ yearly for heart valves. Generally authorized stockist gets discount on the product from the company hence are able to bag deals easily.<br />
*Pricing: Rate contract is signed with the stockist and all the procedures would be charged as per the “rate” mentioned in the contract .Procurement is done on demand basis.<br />
*Exceptions: If the doctor feels that he needs a Heart Value which has new technology and is still not in "rate contract" list, he can issue a local purchase for that ,hence a new entrant with unique offering can make waves. <br />
Inventory management<br />
*Hospitals keep an inventory of different valves from different manufacturers. The number of heart valve from each manufacturer is actually determined by the surgeons.<br><br />
<br />
'''Procurement of heart valve at the time of surgery:''' <br />
*When a valve is recommended for a patient, the patient has to go procurement dept. to get their valve, the procurement dept then informs the vendor and only after this the vendor would raise the invoice. This is unique because even if the valve is sitting in the hospital, invoice is raised only when it is ready to be implanted into the patient. This is same for every vendor.<br />
*For insurance related patients, the patients have to go to the credit cell of the hospital and then when the credit cell gives a green sign (after the formalities with insurance vendor and patient) the procurement dept. asks to raise the invoice.<br><br />
<br />
'''Margin structure:''' <br />
*Commission varies from company to company but generally the distributor take (20-25%),hospitals take (20-25%).<br />
*Doctors take (10%),perfusionist takes (2%) how ever the data regarding the cut taken by doctors & perfutionists varies from nil to a few percentage in monetary /non monetary terms which generally happens under the table.<br />
<br />
==Pricing landscape==<br />
The major cost of the surgery includes cost of the <br />
*Medical devices<br />
*Procedures<br />
<br />
'''Medical device'''<br />
The heart valve typically costs from INR22,000 ($420) to INR200,000($3,800). <br />
The most cost effective valve is manufactured by TTK. The valve is called TTK Chitra. <br />
Depending upon the type( mechanical, tissue, percutaneous etc)of valve the price could go up to more than INR10 lakhs($18,800).<br />
<br />
'''Procedure'''<br />
The hospitals generally charge a fixed amount on money for the whole procedure. In Tier 1 cities it is INR2 lakhs($3,800) in most of the hospitals. <br />
<br />
The ratio of cost of device to procedure generally is 30% to 70%. <br />
===Pricing committee===<br />
Each hospital in the chain has a pricing committee which decides the price of valve based on factors such as : <br />
*Profitability<br />
*Handling charges<br />
*Benefit to the patients <br />
Hence price of same valve may be different in a hospital of same chain <br />
===Purchasing committee===<br />
*Some hospitals (generally a chain) have a central committee which directly negotiates with the company on the purchasing price of the Heart Valves<br />
*Purchasing committee has a lot of bargaining power as they deal in huge volumes (Example – Fortis group)<br />
<br />
==Key hospitals & institutions==<br />
[[Image:Key Hospitals.png|thumb|center|700px|Dolcera Analysis]]<br />
===Narayana Hrudayala Hospitals===<br />
Narayana Hrudayalaya is founded by one of the India’s oldest construction company “Shankar Narayana Construction Company”. Narayana Hrudayalaya group currently has 5000 beds in India and aims to have 30,000 beds in the next 5 years in India to become the one of the largest healthcare player in the country.<br />
<br />
'''Narayana Hrudayalaya - Highlights'''<br />
*The largest cancer hospital in the country at the Bangalore campus - 1,400-bed cancer and multispecialty hospital.<br />
*Largest number of Pediatric Heart Surgeries in the world.<br />
*Largest number of Heart Valve Replacements in the world for the year 2007.<br />
*Over 32 heart surgeries performed in a day.<br />
*World leader in endovascular interventions for aneurysm of aorta.<br />
*First hospital in Asia to implant a 3rd generation artificial heart.<br />
*Working on a mission to do a heart operation for US$800 from point of admission to point of discharge in next 3 years.<br />
====NH Institute of Cardiac Sciences, Bangalore====<br />
Narayana Hrudayalaya is located close to the Electronics City of Bangalore covering 26 acres of land with a building to accommodate 1000 beds, 26 operation theaters and infrastructure to perform 70 heart surgeries a day. Within the first 5 years of commissioning this institution, currently 25 heart surgeries are done on a daily basis, out of them about 30% are on children with heart problem. Rest of them is adult open-heart surgeries.<br><br />
The institute is one of the world’s largest pediatric heart hospitals. It is the brainchild of renowned cardiac surgeon Dr. Devi Shetty, who performed over 15,000 heart operations.<br />
====Heart Valve Procedures====<br />
'''The Ross Procedure'''<br><br />
The Ross Procedure, also known as Pulmonary valve translocation, was developed by Donald Ross in 1967.This operation uses the patient’s own pulmonary valve and part of the main pulmonary artery as a unit to replace the aortic valve and ascending aorta. A homograft valve is harvested from a cadaver, is then placed in the pulmonary position. The pulmonary valve is identical in shape, size, and in fact stronger than the aortic valve and is therefore an ideal replacement for the diseased aortic valve. Narayana Hrudayalaya has a full fledge functioning homograft heart valve bank for the benefit of the needy patients. The surgeons of the Narayana Hrudayalaya have a large experience in successful valve replacements using homografts and Ross operations. These operations are being done only in very few centres in our country. Surgeons at Narayana Hrudayalaya have performed about 100 of these procedures with excellent results. They are perhaps one of the most experienced surgeons in the World in performing operations like Bental Procedure for Aortic Aneurysm and Aortic Arch replacement surgery for dissecting Aneurysm of Aorta.<br />
<br><br />
<br />
'''Mitral Valve Repair in New Born Babies and Infants'''<br><br />
Mitral Valve leakage is a dreadful condition affecting small percentage of children suffering from congenital heart disease. Only option for these children is repair of the valve, which is done on a regular basis at Narayana Hrudayalaya.<br />
<br><br />
<br />
'''Ross's Procedure for Aortic Stenosis'''<br><br />
Best treatment option for Aortic Stenosis is Ross's Procedure in which the patient's own pulmonary valve is used to replace the aortic valve and in the place of pulmonary valve a homograft taken from a dead body is replaced.<br />
====Procedure Charges====<br />
Narayana Hrudayala uses economies of scale to keep the cost of treatment low.<br><br />
'''Heart Surgery'''<br />
*The procedure cost is arounf INR 110,000 for a fully paid heart surgery <br />
*Narayana Hrudayala also offers free treatment for few who cannot afford the procedure <br />
*It has tie-ups with health foundations and offer them discounted price of INR 60,000 to 70,000 <br />
<br><br />
Unlike other hospitals, the bulk of its profits come from the out- patients ward, where the cost to the patient is low but the margins are as high as 80 percent. The number of walk-in patients remains high because they know the cost of surgery will be subsidised should they need it.<br />
<br />
Source:[http://ibnlive.in.com/news/forbes-india-dr-shetty-and-his-business-with-a-heart/96567-7.html IBN Live Article]; [http://haveaheart.in/projects/heart-surgeries-for-poor/ Have a heart foundation]<br />
<br />
====Doctor Profiles====<br />
'''Dr. Avery Mathew'''<br><br />
'''Email''': dravery.mathew@hrudayalaya.com<br><br />
'''Gender''': Male<br><br />
'''Designation''': Senior Consultant Cardiac Surgeon<br><br />
'''Brief Profile''': He has done M.Ch(Cardiothoracic) in Kasturba Medical College,Mangalore His forte lies in Aortic Aneurysms Surgery, besides Coronary Artery and Valve Surgery.<br />
<br><br />
<br />
'''Dr. Binoy C, MCh'''<br><br />
'''Gender''': Male<br><br />
'''Designation''': Consultant Cardiac Surgeon<br><br />
'''Brief Profile''': Dr Binoy completed his training in cardiac surgery at the prestigious Seth G.S Medical College and King Edward Memorial Hospital at Mumbai and The Royal Prince Alfred Hospital at Sydney, Australia. His fields of interest and expertise include Total Arterial Coronary Revascularization procedures using bilateral Internal Mammary Arteries, aortic surgeries and Pulmonary Thrombo Endarterectomy. He also leads the Extra Corporeal Membrane Oxygenation (ECMO) programme in the hospital.<br />
<br><br />
<br />
'''Dr. Chinnaswamy Reddy H M, DNB(Gen. Sur.), DNB(CTS), FPCS'''<br><br />
'''Gender''': Male<br><br />
'''Designation''': Senior Consultant Cardiac Surgeon<br><br />
'''Brief Profile''': He has done M.Ch(Cardiothoracic and Vascular Surgery) in Jayadeva Institute of Cardiology,Bangalore University. He specializes in Bex-Nikaidoh operation, REV operation, Double-switch Ross operation and the latest Cone Reconstruction of Tricuspid Valve in Ebstein\'s Anamoly.<br />
<br />
===Sri Jayadeva Institute of Cardiovascular Sciences and Research===<br />
====Overview====<br />
Sri Jayadeva Institute of Cardiovascular Sciences & Research is a Government owned Autonomous Institute and is offering super specialty treatment to all Cardiac patients. It has got 600 bed strength with State of Art equipments in the form of 4 Cathlabs, 4 Operation Theaters, Non-Invasive Laboratories and 24 hours ICU facilities. Presently on an average 800-1000 patients are visiting this hospital every day and annually 21,500 In patients are treated. About 2500 Open Heart Surgeries, 8500 Coronary Angiograms, 3500 Procedures including Angioplasties and Valvuloplasties are done in this hospital. The prevalence of heart attach, which was 2% in 1960 has increased to 12% in 2008. Unfortunately heart attack and other related heart ailments steadily increasing among the poor people. 70% of the patients who comes to our hospital are well below the poverty line. The consumables used for various procedures like Open heart surgeries (Valve replacement), Angioplasty procedures, Pacemaker procedures are becoming very expensive, however quality treatment is given at affordable cost. Well equipped special ward facilities with round the clock angioplasty services are also provided.<br />
<br><br />
*URL:[http://www.jayadevacardiology.com/index.html Hospital Website]<br />
*Location: Bangalore<br />
====Heart Valve Replacement Procedures====<br />
[[Image:Valve Replacements.png|center|thumb|700px|Source:[http://www.jayadevacardiology.com/statistics.html Hospital Statistics]]]<br />
<br />
====Procedure Charges====<br />
'''Cost of Valve Replacement Procedure (MVR / AVR / DVR ) INR Rupees'''<br />
[[Image:Procedure charges.png|center|thumb|607px|Source:[http://www.jayadevacardiology.com/procedure_charges.html Hospital Website]]]<br />
*Any additional Devices / Implants/ Drugs used shall be charged extra.<br />
*Wherever the procedure rates are not listed in the CGHS website, SJICR Category rates shall be applicable. <br />
*Deluxe Ward Charges – Rs.2500/day<br />
*Special Ward Charges – Rs. 975/day<br />
*Procedure/Investigation charges vary for CGHS, ESI, Yeshasvini and other boards. please contact SJIC for more details.<br />
*SJIC shall have sole discretionary powers to modify tariff without notice.<br />
<br />
====Doctor Profiles====<br />
'''Dr. C.N. Manjunath'''<br />
M.B.B.S, M.D (Gen.Medicine), D.M (Cardiology)<br><br />
Director and Prof. & HOD of Cardiology<br><br />
'''Degree College University Year of passing'''<br />
M.B.B.S M.M.C Mysore 1982<br><br />
M.D. (Gen. Medicine) B.M.C Bangalore 1985<br><br />
D.M. (Cardiology) K.M.C Mangalore 1988<br><br />
'''Marital Status''' : Married<br><br />
'''Nationality''' : Indian<br><br />
'''Designation''' : Professor & Head of Cardiology;Director <br><br />
Sri Jayadeva Institute of Cardiovascular<br><br />
Sciences & Research, 9th Block Jayanagar<br><br />
Bannerghatta Road, Bangalore – 560069.<br><br />
E-mail: cnm_vidhatri@satyam.net.in<br><br />
cnmanjunath@vsnl.net<br><br />
Phone: 080-22977422, 22977433,<br><br />
Direct -080 – 22977456 fax: 26534477<br><br />
Cell Phone: 9844006699<br><br />
Residence: 26692155, 26697558<br><br />
<br />
==Key Opinion Leaders==<br />
The surgeons are the decision makers regarding the kind and make of the valve. Almost in all hospitals surgeons recommend the type and brand of the device. Dolcera team performed a research exercise that involved interviewing doctors at top hospitals. During this exercise we found that the following factors are taken into account while taking a decision for selecting a heart valve:<br />
<br />
# Indication of patient<br />
# Paying capacity<br />
# Quality of valve(durability)<br />
# Supply/ Availability<br />
# Need for anti-coagulation<br />
# Haemodialysis dynamics<br />
<br />
<br />
'''The Dolcera team found following insights from the discussions with surgeons:'''<br />
<br />
# Patients are not aware of the brands available in the market.<br />
# Sometimes patients ask for a foreign valve only.<br />
# Patients usually have information about tissue or mechanical valve and want to know which one was used the procedure and why?<br />
<br />
<br />
Here is a list of few of the key influencers in the industry:<br />
<br />
Please click on the names to get biographies of Physicians<br />
<br />
# [[Dr. Vivek Jawali]]<br />
# [[Dr. Ashok Seth]]<br />
# [[Dr. Naresh Trehan]]<br />
# [[Dr. Ajay Kaul]]<br />
# [[Dr. Surendra Nath Khanna]]<br />
# [[Dr. Z. S. Meharwal]]<br />
# [[Dr. Sunil K Kaushal]]<br />
# [[Dr. Y. K. Mishra]]<br />
# [[Dr. Sanjay Gupta]]<br />
# [[Dr. Vijay Dikshit]]<br />
<br />
<br><br />
<br />
==Market Drivers==<br />
===Rising middle-class and ageing population===<br />
India has a population close to 1.1 billion people, making it the second most populated country behind China,<br />
and 5% of them are over 65 years of age. And unlike China, India does not impose restrictions such as ‘onechild’<br />
policy upon its citizens. Over the next couple of decades, India is expected to surpass China as the<br />
world’s most populous country. During the forecast period to 2015, India is expected to reach 1.3 billion in<br />
total population. And as the ageing population grows, the demand for healthcare services and products will<br />
also rise. The most important driver for India however, is the rising middle-class population that will exceed<br />
450 million by 2015. Although most of the population cannot afford premium healthcare, there are 100 million<br />
middle-class people with an annual income of over $5,000 who demand quality healthcare. While $,5000<br />
may be a small amount in comparison to international standards, in terms of purchasing power parity (PPP),<br />
Indian citizens can enjoy premium health services within this income bracket on a par with people in<br />
developed nations.<br />
<br />
===Medical Tourism===<br />
Medical tourism has been gaining more attention resulting in an increased influx of foreign patients into India<br />
over the past seven to eight years. About 50% of specialized urban hospitals are actively focusing on tapping<br />
medical tourists to grow their business and gain international recognition.<br />
[[Image:Medical Tourism.png|thumb|center|400px|Source:Interviews with experts in the field]]<br />
'''Cost effectiveness against developed countries(Medical Tourism)'''<br />
<br />
India is fast becoming a popular destinations for procedures like heart valve replacement surgeries primarily due to:<br />
* Cost savings ranging from 70-80%<br />
* Presence of highly educated, skilled and experienced surgeons to the same degree as United States. <br />
* The patient may remain in hospital for a prolonged recovery period after the surgical procedure. A hospitalized recovery allows one to heal faster than if he/she were discharged to recover at home as is the practice in the United States. <br />
<br />
The following table provides a snapshot of the comparative cost (in USD) for major heart procedures across 6 countries:<br />
<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"<br />
|align = "center" bgcolor = "#538DD5" rowspan = "2"|'''Procedure'''<br />
|align = "center" bgcolor = "#538DD5" colspan = "6"|'''Country (cost in USD)'''<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|'''Costa Rica'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Mexico'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Thailand'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''Singapore'''<br />
|align = "center" bgcolor = "#FDE9D9"|'''India'''<br />
|align = "center" bgcolor = "#C5D9F1"|'''USA'''<br />
|-<br />
|'''Heart Valve Replacement'''<br />
|align = "right"|18,000<br />
|align = "right"|21,500<br />
|align = "right"|11,500<br />
|align = "right"|15,500<br />
|align = "right" bgcolor = "#FDE9D9"|'''12,000'''<br />
|align = "right"|170,000<br />
|-<br />
|'''Angioplasty'''<br />
|align = "right"|11,000<br />
|align = "right"|16,500<br />
|align = "right"|14,500<br />
|align = "right"|14,500<br />
|align = "right" bgcolor = "#FDE9D9"|'''10,500'''<br />
|align = "right"|61,500<br />
|-<br />
|'''Heart Bypass'''<br />
|align = "right"|29,000<br />
|align = "right"|26,500<br />
|align = "right"|13,000<br />
|align = "right"|22,500<br />
|align = "right" bgcolor = "#FDE9D9"|'''11,000'''<br />
|align = "right"|127,000<br />
|-<br />
|}<br clear="all"><br />
<br />
Source: [http://books.google.co.in/books?id=Q1Un-gGsozMC&pg=PA122&lpg=PA122&dq=100000+heart+valve+replacements+in+India&source=bl&ots=UH_o0vDMQz&sig=8K4HdCO40ldWiWN7fgDfHQDIIZ4&hl=en&sa=X&ei=WVRrT4LDGY6qrAeEtaG8Ag&sqi=2&ved=0CF0Q6AEwBQ#v=onepage&q=100000%20heart%20valve%20replacements%20in%20India&f=false Medical Tourism by John Connell], [http://www.pr-inside.com/affordable-low-cost-heart-valve-replacement-r1738717.htm PR Inside News], [http://www.worldmedassist.com/india/heart-valve-replacement-surgery/ World Med Assist]<br />
<br />
<br><br />
<br />
==Recent Trends==<br />
'''Transcatheter Aortic Valve Implantation (TAVI)'''<br />
<br />
'''Description:'''This technique involves insertion of a miniaturized valve through a catheter from the groin. The deployed valve is later inflated at the site of the aortic valve<br />
<br />
'''Procedures in India:''' TAVI is still in nascent trial stage in India. In mid of March 12, a team of doctors at Delhi's Fortis Hospital headed by Dr Ashok Seth operated three patients using TAVI.<br />
<br />
'''Cost of surgery in India:''' The cost of procedure is $29,350 USD which includes the cost of valve $ 21,500 USD (approx).<br />
<br />
'''Regulatory affairs:''' Sources at the health ministry revealed that a dialogue is on between Drug Controller General of India and the manufacturing company. Cost is said to be the bone of contention.<br />
<br />
'''TAVI Procedure – Insights from Doctors in India'''<br />
<br />
*Dr Ashok Seth one of the most reputed cardiologist of India is Chairman, Cardiac Sciences, Fortis Escorts Heart Institute<br />
"''The valve is known to last up to 15 years but its efficacy for the Indian population is still being assessed.''“<br />
*Dr Vivek Gupta a senior interventional cardiologist in Apollo Hospital, Delhi <br />
“''Mass availability of the valve is also an issue, as there is only one company manufacturing it''”<br />
*Prof RK Saran, Head of Lari Cardiology at Chhatrapati Shahuji Maharaj Medical University<br />
“''The disease of AVS is on the rise in Indian population affecting close to 1 million elders every year.''”<br />
<br />
Source: [http://articles.timesofindia.indiatimes.com/2012-03-28/lucknow/31249104_1_transcatheter-aortic-valve-implantation-open-heart-heart-surgery Timesofindia]<br />
<br />
==Recent Developments==<br />
<br />
'''India'''<br />
#March,2012 - [http://www.rediff.com/business/report/budget-2012-sme-medical-devices-budget-unveils-moves-to-drive-growth/20120319.htm Medical devices: Budget unveils moves to drive growth]<br />
#March,2012 - [http://articles.timesofindia.indiatimes.com/2012-03-28/lucknow/31249104_1_transcatheter-aortic-valve-implantation-open-heart-heart-surgery New technique offers alternative to vulnerable heart patients]<br />
#March,2012 - [http://www.4-traders.com/FORTIS-HEALTHCARE-INDIA-L-9059727/news/FORTIS-HEALTHCARE-INDIA-LTD-India-s-First-Successful-Percutaneous-TAVI-Performed-At-Fortis-Escorts-14219316/ India’s First Successful Percutaneous TAVI Performed at Fortis Escorts]<br />
#November,2011 - [http://www.expresshealthcare.in/201011/market17.shtml India Medtronic Launches Pulmonary Valve Replacement Therapy for Congenital Heart Disease Patients]<br />
<br />
<br />
'''US'''<br />
#March,2012 - [http://www.bloomberg.com/news/2012-03-26/edwards-sapien-safely-fixes-aortic-valves-at-two-years-in-study.html Edwards Sapien Safely Replaces Aortic Valves at Two Years]<br />
#November,2011 - [http://www.24-7pressrelease.com/press-release-rss/colibri-heart-valve-will-present-at-upcoming-23rd-annual-transcatheter-cardiovascular-therapeutics-scientific-symposium-244953.php Colibri Heart Valve Will Present at Upcoming 23rd Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium]<br />
#November,2011 - [http://www.nytimes.com/2011/11/03/business/fda-approves-less-invasive-heart-valve-replacement.html Less Invasive Heart Valve Replacement Is Approved]<br />
#March,2011 - [http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1299607475454&lang=en_US Medtronic Announces Global Launch of New Heart Valve Repair Ring Designed to Adapt to Heart’s Natural Valve]<br />
<br />
=Key Players=<br />
==Overview==<br />
[[Image:Major products in india.png|thumb|600px|center]]<br />
==Key Players==<br />
===Medtronic===<br />
*Medtronic is present in India since 1979.It is headquartered out of Mumbai with offices all over the country and a total headcount of 318 employees spread across the country. <br />
*Medtronic has sales offices in New Delhi, Kolkata, Bangaluru, Hyderabad, Chennai, Vadodara and Cochin.<br />
*Medtronic is a leader in biological valves today. <br />
*Medtronic have adapted to the Indian market well as regards the price is concerned.<br />
*Medtronic recently has discontinued their blockbuster model Hall, thus sales have suffered drastically.<br />
===St Jude Medical===<br />
*St. Jude Medical company’s Indian operations have grown since it launched a wholly owned subsidiary in the local market six years ago. <br />
*St. Jude Medical currently is headquartered and also has distribution center in Hyderabad<br />
*Sales offices in New Delhi, Kolkata and Mumbai — three of the four major metros in India.<br />
*Warehouses located in Delhi, Mumbai, Bangalore, Ahmedabad, Kolkata and Chennai.<br />
*St Jude is today the undisputed winner in mechanical heart valve market revenue wise.<br />
*St Jude have adapted to the Indian market well as regards the price is concerned .St Jude started with high prices but then compromised on prices and sales went up very high, now they are the market leaders. That’s because patients in emerging markets often contend with cost-related accessibility issues which they have addressed well.<br />
===Edwards Life sciences===<br />
*Edwards have been present in India since long but their presence has not been significant when compared to St. Jude or Medtronic.<br />
*The company is headquartered in Mumbai & has a sales force of 30 employees<br />
*Edwards products are good but priced very high as compared to competition.<br />
*Edwards is concentrating on percutaneous valves costing 30000 $ in US (15 lakhs in India) which has very less takers.<br />
*No presence in minimally invasive products (huge market), now have Port Access also, but have not introduced their products in India.<br />
===TTK===<br />
*TTK Healthcare's most significant contribution to healthcare is the manufacture and distribution of India's first indigenous heart valve prosthesis - the tilting-disc TTK Chitra Heart Valve.<br />
*This is the only Indian-made heart valve and is the most price-friendly in the world. So far, over 50,000 TTK Chitra Heart Valves have been successfully implanted in patients.<br />
*TTK Chitra Heart Valves has been tested in various International Laboratories and the findings were published in leading journals. The results indicate that the performance of TTK Chitra Heart Valves is comparable with any other valves available in the market.<br />
*Manufacturing facility is located at Kazhakottom in Trivandrum India<br />
*TTK Chitra Heart Valves are being used in over 250 major cardiac centers in the country with a total of over 55,000 implants.<br />
*The Chitra TTK Valves are leader in sales number wise .In year 2011-12 10,425 Chitra TTK mechanical valves were sold (Source: annual report) <br />
===New entrants===<br />
*Sorin & ATS have also been trying to venture into India market but do not have any significant presence in India as of now. Recently they have been focusing on India ,by poaching sales force of existing players.<br />
==Comparative Analysis==<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Comparative Analysis'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Medtronic'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''St. Jude'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Edwards'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''TTK'''</font><br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Product'''<br />
|align = "center" bgcolor = "#DBE5F1"|Product line is good, but untimely product recalls have caused losses<br />
|align = "center" bgcolor = "#DBE5F1"|Huge portfolio expanded very rapidly<br />
|align = "center" bgcolor = "#DBE5F1"|High end products serves only niche segments<br />
|align = "center" bgcolor = "#DBE5F1"|Single product (Best Seller)<br />
|-<br />
|align = "center"|'''Pricing'''<br />
|align = "center"|Adapted to Indian market competitively priced<br />
|align = "center"|Adapted to Indian market competitively priced<br />
|align = "center"|Priced very high as compared to peers<br />
|align = "center"|Unique selling proposition. Priced lowest in world deal in huge volumes<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Marketing'''<br />
|align = "center" bgcolor = "#DBE5F1"|Specialized in introducing new technology & key opinion leader management<br />
|align = "center" bgcolor = "#DBE5F1"|Focus on aggressively reaching out to a large set of surgeons as they deal low margins & high volumes<br />
|align = "center" bgcolor = "#DBE5F1"|Not much focus<br />
|align = "center" bgcolor = "#DBE5F1"|Tie up with Insurance schemes has benefited in a huge way<br />
|-<br />
|align = "center"|'''Training'''<br />
|align = "center"|Conduct training<br />
|align = "center"|Not much focus<br />
|align = "center"|Conducts training<br />
|align = "center"|Not much focus<br />
|-<br />
|}<br />
<br />
=Recommendations=<br />
==Institutional challenges in India (a special case)==<br />
[[Image:Institutional challenges.png|thumb|center|700px|Dolcera Analysis]]<br />
==India strategic outlook - Phase wise approach==<br />
*By targeting at key hospital chains & few key opinion leaders in selected cities most of the Indian market can be covered as all the procedures are concentrated at few sites in exceptionally large volumes. We can have a look at India in a brief snap shot below.<br />
[[Image:major hospitals.png|thumb|center|600px|Major hospitals in India and their presence across cities]]<br />
Note:Fortis Healthcare has acquired Wockhardt Hospitals<br />
<br />
==Find hotspots - Attractive customer segments==<br />
*The customers can be segmented in India as follows. The local segment with global quality aspirations is growing at a very fast pace concentrated in most of the metropolitans.<br><br />
[[Image:Customer segments.png|thumb|center|700px|Dolcera Analysis]]<br />
===Segment champions===<br />
# Bottom of the pyramid: TTK<br />
# Local segment: St. Jude<br />
# Local segment (global aspirations): Medtronic<br />
# Global outlook: Medtronic, Edwards<br />
<br />
==Key opinion leader management==<br />
'''Government Hospitals'''<br><br />
The Head of department, who is generally the most experienced surgeon would test a new heart valve initially with few surgeries, depending upon his experience he would recommend the use of new heart valves and generally .The surgeons need to be convinced about the safety & durability of the valve through training various online illustration and manuals that talk in detail about the procedure .Generally they are interested in relative comparison with competitors. Also the approval of new heart valve is given by the respective head of dept. at the state / government owned institutions .The list of approved valves are allowed to bid for the tender. <br><br />
<br />
'''Private hospitals'''<br><br />
Especially the chain of hospitals, have key doctors that drive the most of business, they have a big team of cardiac surgeons under them. For example Dr Vivek Jawali at Fortis Bangalore has under him team of 17 cardiac surgeons which performs almost 25 procedures daily (not all heart valves) .His opinion is regarded very highly in the industry. In private hospital the procurement & pricing is generally handled by a separate committee hence the doctors in that committee are also very crucial. <br />
==Training==<br />
*Training conducted in the form of videos, literature and workshops is highly appreciated and well received as suggested by surgeons.<br />
*The module of the current training and interactive programs is a concern for the doctors. They feel it is more marketing oriented and less knowledge oriented. In its present form there is no value add; surgeons thus avoid them. <br />
*Surgeons want to be technological partners; having them in the whole technological framework will prove fruitful<br />
==Sales & distribution plan==<br />
*Focus on selected cities: As the most of the procedures are carried out in capital city of the state or some prominent town .Mostly the traffic is routed from other cities to the capital city due to availability of proper infrastructure in big cities only. The sales person can be recruited state wise so that they can cater to both Tier 1 &Tier 2 cities with focus initially on Tier 1 city. For example in state of Karnataka has 3500- 5000 procedures are conducted every year out of which 90% of demand is from Bangalore, the capital of the state. Hence focusing on key institutions in metropolitans would cover most of the market. <br />
*The sales person should be allocated to a particular state with major focus on key accounts & key opinion leaders in the capital city and reach out to surgeons based on the priority list. The doctors should be classified in three categories as mentioned below. The top most should have the highest priority.<br><br />
[[Image:Sales plan.png|thumb|center|700px|Dolcera Analysis]]<br />
*Key opinion leaders: Most important surgeons, monthly 4 visits should be conducted, there are doctors are instrumental in getting new technologies in vogue. Should be partnered with in various activities such as awareness programs, radio shows, new product launches. Their insight would help a lot in framing strategy for the company. Conducting special training programs can be of great help to both the surgeon and the firm <br />
*Head of Departments & other key decision makers: They can drive immediate business hence need to follow up rigorously 3-4 times in a month.<br />
*Other surgeons: These are not decision makers but as they also conduct a lot of procedures & are a part of the team they too require follow-ups twice in month.<br />
*For Government organizations: These are tough to handle as the approval channel is complex as the gatekeeper are more and the organizations are highly bureaucratic in nature.<br />
==Unmet needs==<br />
*Paucity of statistical data: There is no company like MAT & OMR that keeps records of patients /prescriptions in pharmaceutical industry; hence no statistics are available to ascertain the exact size of the patients that do not undergo heart valve surgery. Hence interviewing experts in the field can help us finding the unmet needs & the exact potential of the market.<br />
*Underserved market: According to our survey doctors /surgeons say that almost 35-40 % of patients do not get the surgery done. Reasons being scarcity of funds, while few also do not get operated at a later age as they avoid taking risk do not find much utility in getting operated.<br />
*OT Register: Exact demand and log can be found in Operation theatre OT registration which contains detail such as of name patient, size of heart valve used, company name , model number & other details. These details are generally not accessible however some information can be fetched by having good rapport with Hospital staff. Building relationship with surgeon is the key to success in Heart valve sales.<br />
==Cost Reduction==<br />
*Following steps should be taken at various fronts:<br />
[[Image:cost reduction.png|thumb|center|700px|Dolcera Analysis]]<br />
=Strategy formulation=<br />
==Data collaboration & content analysis==<br />
[[Image:data collaboration1.png|thumb|center|700px|Dolcera Analysis]]<br />
<br />
==Developing strategy options & selection==<br />
[[Image:strategy options.png|thumb|center|700px|Dolcera Analysis]]<br />
==Review & ongoing assessment==<br />
[[Image:review.png|thumb|center|700px|Dolcera Analysis]]</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=10503Main Page2012-05-29T12:54:15Z<p>Venkata.reddy: /* Business & Information Research Services */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Template - Production Of Therapeutic Glycoproteins|Production of Therapeutic Glycoproteins]]<br />
* [[Market Research Tools Landscape]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
* [https://www.dolcera.com/auth/dashboard_multicategory/dashboard.php?workfile_id=130 Opioid Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Strategic Insights:Heart Valve Replacement Market - India]]<br />
* [[Impact on Sales of a Drug going Off-Patent]]<br />
* [[Application of Conjoint Analysis for Total Knee Replacement Surgery Alternatives]]<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[China ICU Ventilator Market]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
* [[Asset Valuation Dashboard]]<br />
* [[Transplant Diagnostics (HLA) Market Landscape]]<br />
* [[Indian Pharma Industry - Distribution & Sales Force Structure]]<br />
* [[Breast Reconstruction Market Landscape]]<br />
* [[Lumpectomy and Mastectomy Trends]]<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile |Samsung Electronics Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[Patent Valuation]]<br />
* [[Automatic Faucets]]<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
* [[Dashboard Technical Specifications]]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
* [[Landscape report for HEMT]]<br />
* [[Nanoemulsions in Foods]] <br />
* [[Variable Valve Timing - Sample]]<br />
<br />
==== Templates: ====<br />
<br />
<b> Food : </b><br />
* [[Nanoemulsions in foods]]<br />
* [[Campylobacter control in meat]]<br />
* [[Antioxidants form olive waste]]<br />
* [[phytosterol and phytostanols]]<br />
* [[Phospholipids and Sphingolipids of Milk]]<br />
* [[Cheese analog]]<br />
<br />
<b> Packaging : </b><br />
* [[Plastic aerosols]]<br />
* [[Dispenser with applicator]]<br />
*[[Biodegradable packaging for liquids]]<br />
<br />
<b> Cosmetics: </b><br />
*[[Enhanced bioavailability of skin whitening actives in topical applications]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
|-<br />
|}<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Market_size_revised.png&diff=9989File:Market size revised.png2011-11-29T09:07:12Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Gastrointestinal_Endoscopy_-Landscape_Report&diff=9988Gastrointestinal Endoscopy -Landscape Report2011-11-29T09:06:51Z<p>Venkata.reddy: /* Market Size */</p>
<hr />
<div>==Overview==<br />
===Introduction===<br />
[[Image:Gastrointestinal Tract.png|thumb|right|500px|'''Gastrointestinal Tract''']]<br />
'''Gastrointestinal Endoscopy''' deals with the endoscopic examination, therapy or surgery of the gastrointestinal tract. Gastrointestinal Tract generally refers to the digestive structures stretching from the mouth to anus, but does not include the accessory glandular organs such as liver, billary tract, panceras. The gastrointestinal tract is categorized into various sections, these include:<br />
*'''Intestines''': The section of the alimentary canal from the stomach to the anal canal, includes the large intestine and small intestine.<br />
*'''Lower Gastrointestinal Tract''': The segment of gastrointestinal tract that includes the small intestine below the duodenum, and the large intestine.<br />
*'''Mouth''': The oval-shaped oral cavity located at the apex of the digestive tract and consisting of two parts: the vestibule and the oral cavity proper.<br />
*'''Pharynx''': A funnel-shaped fibromuscular tube that conducts food to the esophagus, and air to the larynx and lungs. It is divided into the nasopharynx; oropharynx; and hypopharynx (laryngopharynx).<br />
*'''Upper Gastrointestinal Tract''': The segment of gastrointestinal tract that includes the esophagus, stomach and the duodenum.<br />
(Source: [http://www.ncbi.nlm.nih.gov/mesh/68041981 MeSH Database])<br />
<br />
<br />
===Procedures===<br />
Currently, the most commonly used imaging methods for detection of gastrointestinal disorders, including disorders of the small intestine, are<br />
endoscopy and radiological imaging.<br><br />
A traditional endoscope is a device consisting of a flexible tube and an optical system. There are several types of endoscopic procedures used to<br />
identify disorders in the gastrointestinal tract. The basic endoscopic procedures available include:<br />
[[Image:upper endoscopy.jpg|thumb|right|300px|[http://www.thaimedicalnews.com/what-is-endoscopy-gastrointestinal-digestion-disorder-exam/2008/04/22/ Upper Endoscopy]]]<br />
* '''Upper Endoscopy''': In upper endoscopy, the physician inserts an endoscope, which is an approximately 3.5 foot long tube, through the patient’s mouth. In esophagogastroduodenoscopy, or EGD, the gastroscope passes down the esophagus and into the stomach and duodenum for visual examination. In esophagoscopy, only the esophagus is viewed.<br />
* '''Colonoscopy''': In colonoscopy, the physician inserts a colonoscope, which is an approximately 5.5 foot long endoscope, into the patient’s colon through the anus. Colonoscopy is the primary method for detecting disorders of the colon and is the standard screening tool for early detection of colon cancer.<br />
* '''Push Enteroscopy''': Push enteroscopy involves the insertion of an approximately six-foot long push enteroscope into the mouth. Due to the length and curvature of the small intestine, push enteroscopy enables the physician to view only the first one-third of the small intestine. The procedure is time consuming and difficult to perform for the physician and significantly more difficult to bear for the patient compared to traditional endoscopy.<br />
* '''Double Balloon Endoscopy''': The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is a tube that fits over the endoscope, and which is also fitted with a balloon. The procedure is usually done under general anesthesia, but may be done with the use of conscious sedation.<br />
<br><br />
==GI Imaging==<br />
Gastrointestinal endoscopy is undergoing major improvements, which are driven by new available technologies and substantial refinements of optical features. Detection, characterization and confirmation are essential steps required for proper endoscopic diagnosis. Optical and nonoptical methods can help to improve each step; these improvements are likely to increase the detection rate of neoplasias and reduce unnecessary endoscopic treatments. Furthermore, functional and molecular imaging are emerging as new diagnostic tools that could provide an opportunity for personalized medicine, in which endoscopy will define disease outcome or predict the response to targeted therapy.<br />
[[Image:Key steps to endoscopic diagnosiss.png|thumb|center|1030px|[http://www.nature.com/nrgastro/journal/vaop/ncurrent/full/nrgastro.2011.152.html Key steps to endoscopic diagnosis]]]<br />
<br><br />
Several new technologies are now available for each step, some of them include:<br />
* '''Narrow-Band Imaging(NBI)''' by Olympus America, uses filter to illuminate mucosa at specific wavelength<br />
*'''Fujinon Intelligent Color Enhancement(FICE)''' by Fujinon, uses Spectral endoscopic image processing technology which has been developed to estimate spectral information from RGB image data obtained through a routine endoscopy and to better characterize mucosal tissue structures <br />
*'''I-Scan''' by Pentax Medical, a next generation technology, is a dynamic, multimodal tool revealing the hidden colors, topography, vascularity, and structure of disease. i-SCAN explores the possibility of the first electronic version of chromoendoscopy (e-Chrome™) through the use of complimentary color filters and enhancements<br />
*'''Third Eye Retroscope®''' by Avantis Medical Systems, an additional small-caliber endoscope that can be passed over the working channel of standard colonoscopes with the possibility of retro view—leads to a substantially increased detection of neoplastic changes<br />
*'''Endoflag''' by Endopix, is a single filter, single-pass implementation that processes standard or high-definition video sequences after acquisition<br />
<br><br />
[[Image:GI Imaging.png|thumb|center|1030px|'''Classification of GI Imaging''']]<br />
<br><br />
<br />
<br />
==Product Portfolio Heat Map==<br />
{|align="center"<br />
|<gflash>950 750 http://dolcera.com/upload/files/product_Heat_Map.swf</gflash><br />
|-<br />
|}<br />
==Market Size==<br />
[[image:Market size revised.png|center|900px|thumb|Source: Business Insights, Global Industry Analysts, Inc.]]<br />
<br />
===Major Players===<br />
====Detailed Company Profile====<br />
[[Olympus Corporation]]<br />
<br><br />
====Snapshot Profiles====<br />
* [[Boston Scientific Snapshot| Boston Scientific]]<br />
* [[Conmed Snapshot| Conmed]]<br />
* [[Covidien Snapshot| Covidien]]<br />
* [[Ethicon Endo Snapshot| Ethicon Endo ]]<br />
* [[Fujinon Snapshot| Fujinon]]<br />
* [[Given Imaging Snapshot| Given Imaging]]<br />
* [[Karl Storz Snapshot| Karl Storz]]<br />
* [[Hoya Snapshot| Hoya Corporation]]<br />
* [[Stryker Snapshot| Stryker]]<br />
<br><br />
Source: [[media:kalorama.pdf|Kalorama]], Company website, Company SEC filings <br />
<br><br />
<br />
==M&A Activity==<br />
{|border="2" cellspacing="0" cellpadding="4" width="80%"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font><br />
|align = "Center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Date'''</font><br />
|align = "Center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Details'''</font><br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|1<br />
|align = "right" bgcolor = "#DBE5F1"|Oct-10<br />
|bgcolor = "#DBE5F1"| [http://www.cookmedical.com/newsDetail.do?id=6614 Cook Medical Receives Two Contract Awards with HealthTrust Purchasing Group for Enteral Feeding and GI Endoscopic Supplies]<br />
|-<br />
|align = "Center" |2<br />
|align = "right"|Apr-10<br />
|[http://www.prnewswire.com/news-releases/water-street-healthcare-partners-signs-definitive-agreement-to-sell-sierra-scientific-instruments-to-given-imaging-88791282.html Given Imaging Ltd acquires Sierra Scientific Instruments from Water St Healthcare Partners]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|3<br />
|align = "right" bgcolor = "#DBE5F1"|Apr-10<br />
|bgcolor = "#DBE5F1"| [http://www.fujifilmusa.com/press/news/display_news?newsID=880031 Fujifilm signs a comprehensive Joint R&D aagreement with Fox Chase cancer center]<br />
|-<br />
|align = "Center" |4<br />
|align = "right"|Mar-09<br />
| [http://www.karlstorz.com/cps/rde/xchg/SID-9641E54E-84C58126/karlstorz/hs.xsl/8250.htm KARL STORZ Acquires Global Care Quest]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|5<br />
|align = "right" bgcolor = "#DBE5F1"|Jan-09<br />
|bgcolor = "#DBE5F1"|[http://diagnosticimaging.medicaldevices-business-review.com/news/given_imaging_announces_expansion_of_distribution_agreement_with_fujifilm_090120 Given Imaging Inks Distribution Agreement with FUJIFILM]<br />
|-<br />
|align = "Center" |6<br />
|align = "right" |Dec-08<br />
| [http://www.dotmed.com/news/story/7624/ Given Imaging Ltd. Acquires Medtronic Bravo(R) pH Monitoring Business]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|7<br />
|align = "right" bgcolor = "#DBE5F1"|Nov-08<br />
|bgcolor = "#DBE5F1"| [http://www.smiths.com/press_release_details.aspx?releaseID=356 Smiths Group Acquires Zhejiang Zheda Medical Instrument]<br />
|-<br />
|align = "Center" |8<br />
|align = "right" |Nov-08<br />
| [http://www.viatronix.com/pdfs/PR112408.pdf Visage Imaging Inks Marketing Agreement with Viatronix]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|9<br />
|align = "right" bgcolor = "#DBE5F1"|Jul-08<br />
|bgcolor = "#DBE5F1"| [http://www.fujifilm.com/news/n080730.html FUJIFILM Merges Fujinon<nowiki>’</nowiki>s Endoscope Business into Medical System Business Division]<br />
|-<br />
|align = "Center" |10<br />
|align = "right" |Jun-08<br />
| [http://www.itnonline.com/article/icad-acr-image-metrix-team-initiate-colon-cad-clinical-study ICAD and ACR Image Form Partnership to Initiate Colon-CAD Clinical Study]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|11<br />
|align = "right" bgcolor = "#DBE5F1"|Mar-08<br />
|bgcolor = "#DBE5F1"| [http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_31/ai_n24963346/ Karl Storz Inks Deal with EndoGastric for Marketing EsophyX and StomaphyX]<br />
|-<br />
|align = "Center" |12<br />
|align = "right" |Mar-08<br />
| [http://www.investinisrael.gov.il/NR/exeres/01104877-8720-4F39-8441-BD24EC58D8B9.htm Given Imaging Bags a 5-Year FSS Contract]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|13<br />
|align = "right" bgcolor = "#DBE5F1"|Nov-07<br />
|bgcolor = "#DBE5F1"| [http://business.timesonline.co.uk/tol/business/industry_sectors/technology/article2903365.ece Olympus Takes Over Gyrus Group]<br />
|-<br />
|align = "Center" |14<br />
|align = "right" |Aug-07<br />
|[http://en.wikipedia.org/wiki/Pentax#Merger_with_Hoya PENTAX and HOYA Merge]<br />
|-<br />
|align = "Center" bgcolor = "#DBE5F1"|15<br />
|align = "right" bgcolor = "#DBE5F1"|Apr-07<br />
|bgcolor = "#DBE5F1"|[http://www.news-medical.net/news/2007/06/26/26855.aspx Boston Scientific to acquire Remon Medical Technologies]<br />
|-<br />
|}<br />
<br><br />
==Procedure Volumes==<br />
The three main areas where GI Endoscopy has considerable applications are Colon/Rectum cancer, Obesity (gastric bypass/gastric banding) and Digestive system disorders.<br />
===Colon/Rectum cancer===<br />
[[Image:Colon cancer.png|thumb|right|300px|[http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/figure/A000262.B19222/?report=objectonly Stages of Cancer]]]<br />
Tumors or cancer of the colon or the rectum or both. Colorectal cancer starts in the large intestine (colon) or the rectum (end of the colon). Risk factors for colorectal cancer include chronic ulcerative colitis; familial polyposis coli; exposure to asbestos; and irradiation of the cervix uteri. ([http://www.ncbi.nlm.nih.gov/mesh?term=colorectal%20cancer MeSH]) Colorectal cancer is the third most commonly diagnosed cancer in the world, but it is more common in developed countries.<br><br />
Stages of colon cancer are:<br />
*''Stage 0'': Very early cancer on the innermost layer of the intestine<br />
*''Stage I'': Cancer is in the inner layers of the colon<br />
*''Stage II'': Cancer has spread through the muscle wall of the colon<br />
*''Stage III'': Cancer has spread to the lymph nodes<br />
*''Stage IV'': Cancer has spread to other organs<br />
(For more information on colon cancer [http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/ click here])<br />
====Volumes, Prevalence and Incidence====<br />
*Overall, the '''lifetime risk''' of developing colorectal cancer is about '''1 in 20''' (5.1%). This risk is slightly lower in women than in men.<br />
* Cases estimated in the US in '''2011''' are:<br />
**''' 101,700''' cases of colon cancer <br />
**'''39,510''' cases of rectal cancer <br />
* Overall, colorectal cancer is the second-leading cause of cancer death in Canada.<br />
** In '''2011''', an estimated '''22,200''' Canadians (12,500 men - 9,700 women) will be diagnosed with colorectal cancer and '''8,900''' (5,000 men - 3,900 women) will die from it.<br />
** '''One in 14 men''' is expected to develop colorectal cancer during his lifetime and '''one in 27''' will die from it. <br />
**'''One in 15 women''' is expected to develop colorectal cancer during her lifetime and '''one in 31''' will die from it.<br />
** On average, '''426''' Canadians will be diagnosed with colorectal cancer every week and '''171''' will die from the disease every week.<br />
(Source: [http://www.colorectal-cancer.ca/en/just-the-facts/colorectal/ Colorectal cancer association of Canada] & [http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuide/colorectal-cancer-key-statistics American cancer society])<br />
====Survival Rates====<br />
[[Image:survival rates.png|center|thumb|800px|[http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuide/colorectal-cancer-survival-rates Source:SEERdatabase]]]<br />
====Incidence rates====<br />
The estimated incidence rate of colorectal cancer in 2007 is expressed geography wise below:<br />
<br />
{|align = "center" border="2" cellspacing="0" cellpadding="4" width="45%"<br />
|align = "center" bgcolor = "#8DB4E3"|'''Area'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''Incidence per 100,000 people'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|North America<br />
|align = "center" bgcolor = "#DBE5F1"|17-33.5<br />
|-<br />
|align = "center"|Europe<br />
|align = "center"|17-33.6<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Asia<br />
|align = "center" bgcolor = "#DBE5F1"|17-33.7<br />
|-<br />
|align = "center"|South America<br />
|align = "center"|17-33.4<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Africa<br />
|align = "center" bgcolor = "#DBE5F1"|3.2-17<br />
|-<br />
|}<br />
Source: Kalorama Information Report<br />
<br />
===Obesity (Gastric bypass/Gastric banding)===<br />
A status with '''body weight''' that is grossly above the acceptable or desirable weight, usually due to accumulation of excess fats in the body. The standards may vary with age, sex, genetic or cultural background. In the Body mass index, a '''BMI greater than 30.0 kg/m2''' is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (morbid obesity).[[Image:gastric band.png|thumb|right|300px|[http://weightlosssurgery.ae/gastric-banding-surgery.php Laparoscopic Gastric Banding]]]<br />
The two most common weight-loss surgeries are:<br />
*[http://www.nlm.nih.gov/medlineplus/ency/article/007388.htm Laparoscopic Gastric Banding](also referred as lap band): The surgeon places a band around the upper part of your stomach, creating a small pouch to hold food. The band helps you limit how much food you eat by making you feel full after eating small amounts.<br />
*[http://www.nlm.nih.gov/medlineplus/ency/article/007199.htm Gastric Bypass]: This surgery helps you lose weight by changing how your stomach and small intestine handle the food you eat. After the surgery, you will not be able to eat as much as before, and your body will not absorb all the calories and other nutrients from the food you eat.<br />
====Volumes, Prevalence and Incidence====<br />
* In '''United States''' obesity is estimated to cause an excess '''111,909 to 365,000 deaths per year'''<br />
* '''One million''' (7.7%) of deaths in the '''European Union''' are attributed to excess weight.<br />
* On an average, obesity reduces life expectancy by '''six to seven years''':<br />
** A BMI of 30–35 reduces life expectancy by two to four years<br />
** While morbid obesity (BMI > 40) reduces life expectancy by 10 years<br />
* Large-scale American and European studies have found that mortality risk is lowest at a BMI of 20–25 kg/m2, with risk increasing along with changes in either direction. ([http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960318-4/fulltext Source: thelancet] & [http://jama.ama-assn.org/content/282/16/1530.full jama-ama-assn])<br />
*'''Obesity prevalence rate in USA'''<br />
[[Image:prevalence.png|thumb|center|900px|[http://www.cdc.gov/obesity/data/trends.html Percent of Obese (BMI > 30) in U.S. Adults]]]<br />
<br />
===Digestive system disorders===<br />
Diseases in any part of the gastrointestinal tract or the accessory organs (liver; biliary tract; pancreas). The digestive system disorders are categorized as: <br />
*Biliary Tract Diseases<br />
*Digestive System Abnormalities<br />
*Digestive System Fistula<br />
*Digestive System Neoplasms<br />
*Gastrointestinal Diseases<br />
*Liver Diseases<br />
*Pancreatic Diseases<br />
*Peritoneal Diseases<br />
([http://www.ncbi.nlm.nih.gov/mesh?term=Digestive%20system%20disorders Source: MeSH])<br />
====Volumes, Prevalence and Incidence====<br />
*Hospital visits in USA (Digestive disorders as the primary reason)<br />
[[image:digpri.png|thumb|center|600px|[http://www.cdc.gov/nchs/data/ad/ad374.pdf Source:CDC health statistics report]]]<br />
*Disease wise breakup (Digestive disorders as the primary reason)<br />
[[image:digbreakup.png|center|700px|thumb|[http://www.cdc.gov/nchs/data/series/sr_13/sr13_169.pdf Source: CDCsurvey]]]<br />
*USA and Europe Procedure Volumes<br />
[[Image:provol.png|center|700px|thumb|Source: Kalorama Information; WHO; US Census Bureau; Centers for Disease Control and Prevention]]<br />
NOTE: All values for USA and Europe are in 000's. Data includes both in-patient and out-patient surgical procedures in all populations<br />
==Reimbursements==<br />
===Upper GI/ Colonoscopy===<br />
{|border="2" cellspacing="0" cellpadding="4" width="90%"<br />
|align = "center" bgcolor = "#8DB4E3"|'''CPT Code'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''Procedure'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''2008 National Average Medicare Payment Facility'''<br />
|-<br />
|align = "center"|43250<br />
|Upper GI endoscopy including esophagus, stomach and either duodenum and/or jejunum as appropriate; with removal of tumors, polyps, or other lesions by hot biopsy forceps or bipolar cautery<br />
|align = "center"|$172.91<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43251<br />
|bgcolor = "#DBE5F1"|Upper GI endoscopy including esophagus, stomach and either duodenum and/or jejunum as appropriate; with removal of tumors, polyps, or other lesions by snare technique<br />
|align = "center" bgcolor = "#DBE5F1"|$199.58<br />
|-<br />
|align = "center"|43255<br />
|Upper GI endoscopy including esophagus, stomach and either the duodenum and/or jejunum as appropriate; diagnostic, with control of bleeding any method<br />
|align = "center"|$258.99<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43256<br />
|bgcolor = "#DBE5F1"|Upper GI endoscopy including esophagus, stomach and either the duodenum and/or jejunum as appropriate; with transendoscopic stent placement (includes predilation)<br />
|align = "center" bgcolor = "#DBE5F1"|$233.09<br />
|-<br />
|align = "center"|43258<br />
|Upper GI endoscopy including esophagus, stomach and either the duodenum and/or jejunum as appropriate; with ablation of tumors, polyps, or other lesions not amendable by hot biopsy forceps, bipolar cautery or snare technique<br />
|align = "center"|$244.14<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|45383<br />
|bgcolor = "#DBE5F1"|Colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique<br />
|align = "center" bgcolor = "#DBE5F1"|$307.36<br />
|-<br />
|align = "center"|45384<br />
|Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery<br />
|align = "center"|$248.33<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|45385<br />
|bgcolor = "#DBE5F1"|Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique<br />
|align = "center" bgcolor = "#DBE5F1"|$281.84<br />
|-<br />
|align = "center"|91110<br />
|Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with physician interpretation and report (Visualization of the colon is not reported separately)<br />
|align = "center"|$944.18<br />
|-<br />
|}<br />
<br><br />
===Bariatric Surgery===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="90%"<br />
|align = "center" bgcolor = "#8DB4E3"|'''APC'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''APC Description (Hospital Outpatient Dept)'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''Medicare Payment'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|130<br />
|align = "center" bgcolor = "#DBE5F1"|Level I Laparoscopy (CPT 43659)<br />
|align = "center" bgcolor = "#DBE5F1"|$2,190.81<br />
|-<br />
|align = "center"|135<br />
|align = "center"|Level III Skin Repair (CPT 43887)<br />
|align = "center"|$288.30<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|137<br />
|align = "center" bgcolor = "#DBE5F1"|Level V Skin Repair (CPT 43886, 43888)<br />
|align = "center" bgcolor = "#DBE5F1"|$1,287.06<br />
|-<br />
|align = "center"|141<br />
|align = "center"|Level I Upper GI Procedure (CPT 43999)<br />
|align = "center"|$541.59<br />
|-<br />
|}<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="90%"<br />
|align = "center" bgcolor = "#8DB4E3"|'''CPT Code'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''Procedure'''<br />
|align = "center" bgcolor = "#8DB4E3"|'''2008 National Average Medicare Payment Facility'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43886<br />
|bgcolor = "#DBE5F1"|Gastric reconstructive procedure, open; revision of subcutaneous port component only<br />
|align = "center" bgcolor = "#DBE5F1"|$836.59<br />
|-<br />
|align = "center"|43888<br />
|Removal and replacement of subcutaneous port component only<br />
|align = "center"|$836.59<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43644<br />
|bgcolor = "#DBE5F1"|Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (Roux limb 150 cm or less)<br />
|align = "center" bgcolor = "#DBE5F1"|$1,507.10<br />
|-<br />
|align = "center"|43645<br />
|Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption<br />
|align = "center"|$1,615.27<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43659<br />
|bgcolor = "#DBE5F1"|Unlisted laparoscopy procedure, stomach (Removal and replacement of both adjustable gastric band and subcutaneous port component)<br />
|align = "center" bgcolor = "#DBE5F1"|Carrier Priced<br />
|-<br />
|align = "center"|43770<br />
|Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric band (gastric band and subcutaneous port components)(use modifier - 52 for individual component placement)<br />
|align = "center"|$970.08<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43771<br />
|bgcolor = "#DBE5F1"|Laparoscopy, surgical, gastric restrictive procedure; Revision of adjustable gastric band component only<br />
|align = "center" bgcolor = "#DBE5F1"|$1,107.95<br />
|-<br />
|align = "center"|43772<br />
|Laparoscopy, surgical, gastric restrictive procedure; Removal of adjustable gastric band component only<br />
|align = "center"|$833.72<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43773<br />
|bgcolor = "#DBE5F1"|Laparoscopy, surgical, gastric restrictive procedure; Removal and placement of adjustable gastric band component only<br />
|align = "center" bgcolor = "#DBE5F1"|$1,107.95<br />
|-<br />
|align = "center"|43774<br />
|Laparoscopy, surgical, gastric restrictive procedure: Removal of adjustable gastric band and subcutaneous port components<br />
|align = "center"|$838.29<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43842<br />
|bgcolor = "#DBE5F1"|Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical banded gastroplasty<br />
|align = "center" bgcolor = "#DBE5F1"|$1,071.01<br />
|-<br />
|align = "center"|43843<br />
|Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical banded gastroplasty<br />
|align = "center"|$1,097.67<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43845<br />
|bgcolor = "#DBE5F1"|Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy (50 to 100 cm common channel) to limit absorption (billopancreatic diversion with duodenal switch)<br />
|align = "center" bgcolor = "#DBE5F1"|$1,716.20<br />
|-<br />
|align = "center"|43846<br />
|Gastric restrictive procedure, with gastric bypass, for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy<br />
|align = "center"|$1,416.07<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43847<br />
|bgcolor = "#DBE5F1"|Gastric restrictive procedure, with small intestine reconstruction to limit absorption<br />
|align = "center" bgcolor = "#DBE5F1"|$1,553.19<br />
|-<br />
|align = "center"|43848<br />
|Revision of gastric restrictive procedure for morbid obesity (separate procedure), other than adjustable gastric band<br />
|align = "center"|$1,680.40<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43886<br />
|bgcolor = "#DBE5F1"|Gastric reconstructive procedure, open; revision of subcutaneous port component only<br />
|align = "center" bgcolor = "#DBE5F1"|$287.18<br />
|-<br />
|align = "center"|43887<br />
|Removal of subcutaneous port component only<br />
|align = "center"|$272.32<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|43888<br />
|bgcolor = "#DBE5F1"|Removal and replacement of subcutaneous port component only<br />
|align = "center" bgcolor = "#DBE5F1"|$387.34<br />
|-<br />
|align = "center"|43999<br />
|Unlisted procedure, stomach<br />
|align = "center"|Carrier Priced<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|S2083<br />
|bgcolor = "#DBE5F1"|Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline<br />
|align = "center" bgcolor = "#DBE5F1"|Carrier Priced<br />
|-<br />
|}<br />
<br><br />
==Technology Advancements==<br />
{|align = "center" border="2" cellspacing="0" cellpadding="4" width="60%"<br />
|align = "center" bgcolor = "#B8CCE4"|'''Areas'''<br />
|align = "center" bgcolor = "#B8CCE4"|'''Companies Involved'''<br />
|-<br />
|rowspan = "6"|'''Enhanced Imaging Modalities'''<br />
|Olympus Medical System Corp.<br />
|-<br />
|Pentax Crop. (Hoya Corporation)<br />
|-<br />
|Fujinon<br />
|-<br />
|Mauna Kea Technologies<br />
|-<br />
|KARL STORZ<br />
|-<br />
|SpectraScience Inc.<br />
|-<br />
|'''Robotic-Assisted Endomicroscope'''<br />
|EndoControl Inc.<br />
|-<br />
|'''Wireless Biosensors and Polymers for GI bleeding (Hemostasis)'''<br />
|Pluromed Inc.<br />
|-<br />
|'''Electronic Nose "Smells" Disease'''<br />
|Cyrano Science Inc.<br />
|-<br />
|}<br />
<br><br />
[[Image:chromoendoscopy.png|thumb|center|800px|'''Enhanced Imaging Modalities''': High-definition and virtual chromoendoscopy; (a) White-light imaging during endoscopy; a lesion beside a diverticular is hardly visible (arrow). (b) Closer inspection and image enhancement reveals tubular surface structures (arrows); (c) Virtual chromoendoscopy leads to pseudocolorization and improved visualization of the flat adenoma (arrows); (d) Chromoendoscopy using methylene blue unmasks the full extent of the lesion (arrows).]]<br />
<br></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=File:Data_Sheet.xls&diff=9933File:Data Sheet.xls2011-11-03T10:15:15Z<p>Venkata.reddy: </p>
<hr />
<div></div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=China_ICU_Ventilator_Market&diff=9932China ICU Ventilator Market2011-11-03T10:15:03Z<p>Venkata.reddy: /* Market Size Calculation */</p>
<hr />
<div>==ICU Ventilators==<br />
Intensive-care Unit (ICU) ventilators offer a wide range of breathing patterns, pressure controls, alarms and sensors. They use compressed oxygen and other gases stored in cylinders, ambient air or a mixture of both. Breathing circuits for these ventilators are double-limbed and can be quite complex. These ventilators are made for bedside use in the intensive-care units of hospitals. The key data provided by the device include:<br />
*Airway pressure (analog bar graph & numerical)<br />
*Total breath rate<br />
*Inspiratory to expiratory time ratio<br />
*Exhaled tidal volume<br />
*Exhaled minute volume<br />
*Peak flow<br />
*Inspiratory time<br />
==Market Assessment Model==<br />
The market data for ICU ventilators in China is not readily available in public domain. There are paid reports published by various market research firms in which the data is either modeled using indicators or collected through primary research methods.<br />
<br />
To arrive at the market size of ICU Ventilators in China for 2011, we have used the following methodology. We have considered only adult ICU Ventilators in this study. <br><br />
[[Image:Methodology1.png|center|700px]]<br />
'''Assumptions''': Each ICU bed will be equipped with one ventilator.<br />
<br />
==Number of ICU Beds==<br />
According to 2010 census, the total population of China is estimated as [http://blogs.wsj.com/indiarealtime/2011/04/30/china-vs-india-the-population-numbers/ 1,339,724,852]. The number of hospital beds in China as per [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS] is 22 per 10,000 population. A research paper on [http://ccforum.com/content/14/1/206 critical care medicine in mainland China] which analyzed many papers including the one from China Critical Care Clinical Trial Group (CCCCTG) estimated the % of ICU beds as total number of hospital beds as 1.8%. <br><br />
{|border="2" cellspacing="0" cellpadding="4" width="53%" align="center"<br />
|bgcolor = "#C5D9F1"|China Population, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|1,339,724,852<br />
|-<br />
|Hospital Beds per 10,000 in China<br />
|align = "right"|22<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"| 2,947,395<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.8%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds in China, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|'''53,053'''<br />
|-<br />
|}<br />
<br />
==Estimate of yearly growth in ICU Beds==<br />
China has taken proactive measures to control the population growth and hence it would not be a relevant indicator for growth in ICU beds. There are several factors to be considered in estimating the growth rate of ICU beds in China.<br><br />
[[Image:growth drivers2.png|center|600px]] <br><br />
*'''Large and ageing population:''' By 2025, the number of people in China aged above 65 years is estimated to reach 198 million. ''Source: US Census Bureau, International Database, July 2003''<br />
* '''Medical device industry growth:''' China medical device market has grown at a CAGR of 13.6% during 2003-2008 from $9 billion to $17 billion. ''Source: Datamonitor Report'' ; The market for Chinese medical devices in 2011 is estimated to be $23.2 billion and has grown at a CAGR of 11.1% during 2006-2011 period.'' Source: Espicom Business Intelligence''<br />
*'''Insufficient ICU beds in hospitals''' & '''Poor penetration of medical equipment:''' The % of ICU beds in the total hospital beds in China is only 1.8% as compared to 9% in US. It is hard to find an ICU unit in primary level hospitals in China. Only 23.2% of the secondary level hospitals have ICU units. In tertiary level, ICU units are present in 52.5% centers. ''Source: [http://www.criticalcarenews.com/articlePage.aspx?ArticleID=83 ''Critical Care News'']<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="61%" align="center"<br />
|align = "center" bgcolor = "#95B3D7"|'''Country'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of hospital beds per 10,000'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of ICU beds as % of total hospital beds'''<br />
|-<br />
|align = "center"|China<br />
|align = "center"|22<br />
|align = "center"|1.8%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|USA<br />
|align = "center" bgcolor = "#C5D9F1"|31<br />
|align = "center" bgcolor = "#C5D9F1"|9.0%<br />
|-<br />
|align = "center"|France<br />
|align = "center"|73<br />
|align = "center"|2.5%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|UK<br />
|align = "center" bgcolor = "#C5D9F1"|39<br />
|align = "center" bgcolor = "#C5D9F1"|1.2%<br />
|-<br />
|align = "center"|Canada<br />
|align = "center"|34<br />
|align = "center"|3.4%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|Germany<br />
|align = "center" bgcolor = "#C5D9F1"|83<br />
|align = "center" bgcolor = "#C5D9F1"|4.1%<br />
|-<br />
|align = "center"|Netherlands<br />
|align = "center"|84<br />
|align = "center"|2.8%<br />
|-<br />
|}<br />
Source: [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS],[http://www.ncbi.nlm.nih.gov/pubmed/18766102 PubMed Paper]<br />
<br><br />
*'''Government policies and initiatives:''' China put forward plans in 2010 for US$124 billion to be invested in the healthcare reform programme over a three year period until 2012. Hospitals benefit from these reforms leading to faster equipment replacement and and also generating new demand for medical devices. ''Source'': [http://7economy.com/archives/10736 ''7Economy''], [http://www.globalsurance.com/blog/chinas-healthcare-reforms-progress-324520.html ''Globalsurance'']<br />
Based on the above factors the yearly growth rate in number of ICU beds is estimated to be 11.15%.<br />
<br />
==Pricing and Replacements==<br />
*The average price of an ICU ventilator in China is estimated as $ 12,500. In US, the price is between $15,000 - $ 25,000. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The average price of a disposable ICU ventilator circuit in China is estimates as $ 2.5. The price of a disposable ventilator circuit in US is between $4-$5 and that of a reusable circuit is $40-$50. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The number of replacements of disposable circuits in a single year (2011) is estimated to be 80<br />
<br />
==Market Size Calculation==<br />
*The market for ICU Ventilators in China for 2011 is estimated to be $76 Million<br />
*The market for ICU Ventilator Circuits is about $ 12 Million<br />
*Total ICU Ventilators Market is approximately $ 88 Million in China for 2011<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"<br />
|Number of ICU beds in China, 2010<br />
|align = "right"|53,053<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right" bgcolor = "#C5D9F1"|11.5%<br />
|-<br />
|Number of new ICU beds for 2011<br />
|align = "right"|6101<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|6101<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right"|$12,500<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$76,263,837'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total number of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|59,154<br />
|-<br />
|Price of ICU Ventilator Circuit<br />
|align = "right"|$2.5<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of replacements in a year, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|80<br />
|-<br />
|Average cost of Circuits in a year, 2011<br />
|align = "right"|$200<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilator Circuits, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$11,830,842'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total market for ICU Ventilators China, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$88,094,679'''<br />
|-<br />
|}<br />
[[Media:Data Sheet.xls]]<br />
<br />
==Methodology Validation==<br />
The Indian ICU Ventilator market (adult) for the year 2009 was valued at $ 39 Million with volume sales of 1,605 units. Source: Expert Inteviews of Leading Players by [http://www.medicalbuyer.co.in/index.php?option=com_content&task=view&id=2652&Itemid=48 Medicalbuyer] <br />
<br />
The figures using our methodology are coming to $ 40 Million with volume sales of 1,674 for the year 2009. This proves the accuracy of our methodology.<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="63%" align="center"<br />
|bgcolor = "#C5D9F1"|Population India, 2008<br />
|align = "right" bgcolor = "#C5D9F1"| 1,147,995,904<br />
|-<br />
|Hospital Beds per 10,000<br />
|align = "right"|9<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"|1,033,196<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.35%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds, 2008<br />
|align = "right" bgcolor = "#C5D9F1"|13,948<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right"|12.0%<br />
|-<br />
|Number of new ICU beds for 2009<br />
|align = "right" bgcolor = "#C5D9F1"|1674<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2009<br />
|align = "right"|'''1674'''<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right" bgcolor = "#C5D9F1"|$24,230<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2009<br />
|align = "right"|'''$40,555,642'''<br />
|-<br />
|}</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=China_ICU_Ventilator_Market&diff=9931China ICU Ventilator Market2011-11-03T10:13:56Z<p>Venkata.reddy: /* Market Size Calculation */</p>
<hr />
<div>==ICU Ventilators==<br />
Intensive-care Unit (ICU) ventilators offer a wide range of breathing patterns, pressure controls, alarms and sensors. They use compressed oxygen and other gases stored in cylinders, ambient air or a mixture of both. Breathing circuits for these ventilators are double-limbed and can be quite complex. These ventilators are made for bedside use in the intensive-care units of hospitals. The key data provided by the device include:<br />
*Airway pressure (analog bar graph & numerical)<br />
*Total breath rate<br />
*Inspiratory to expiratory time ratio<br />
*Exhaled tidal volume<br />
*Exhaled minute volume<br />
*Peak flow<br />
*Inspiratory time<br />
==Market Assessment Model==<br />
The market data for ICU ventilators in China is not readily available in public domain. There are paid reports published by various market research firms in which the data is either modeled using indicators or collected through primary research methods.<br />
<br />
To arrive at the market size of ICU Ventilators in China for 2011, we have used the following methodology. We have considered only adult ICU Ventilators in this study. <br><br />
[[Image:Methodology1.png|center|700px]]<br />
'''Assumptions''': Each ICU bed will be equipped with one ventilator.<br />
<br />
==Number of ICU Beds==<br />
According to 2010 census, the total population of China is estimated as [http://blogs.wsj.com/indiarealtime/2011/04/30/china-vs-india-the-population-numbers/ 1,339,724,852]. The number of hospital beds in China as per [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS] is 22 per 10,000 population. A research paper on [http://ccforum.com/content/14/1/206 critical care medicine in mainland China] which analyzed many papers including the one from China Critical Care Clinical Trial Group (CCCCTG) estimated the % of ICU beds as total number of hospital beds as 1.8%. <br><br />
{|border="2" cellspacing="0" cellpadding="4" width="53%" align="center"<br />
|bgcolor = "#C5D9F1"|China Population, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|1,339,724,852<br />
|-<br />
|Hospital Beds per 10,000 in China<br />
|align = "right"|22<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"| 2,947,395<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.8%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds in China, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|'''53,053'''<br />
|-<br />
|}<br />
<br />
==Estimate of yearly growth in ICU Beds==<br />
China has taken proactive measures to control the population growth and hence it would not be a relevant indicator for growth in ICU beds. There are several factors to be considered in estimating the growth rate of ICU beds in China.<br><br />
[[Image:growth drivers2.png|center|600px]] <br><br />
*'''Large and ageing population:''' By 2025, the number of people in China aged above 65 years is estimated to reach 198 million. ''Source: US Census Bureau, International Database, July 2003''<br />
* '''Medical device industry growth:''' China medical device market has grown at a CAGR of 13.6% during 2003-2008 from $9 billion to $17 billion. ''Source: Datamonitor Report'' ; The market for Chinese medical devices in 2011 is estimated to be $23.2 billion and has grown at a CAGR of 11.1% during 2006-2011 period.'' Source: Espicom Business Intelligence''<br />
*'''Insufficient ICU beds in hospitals''' & '''Poor penetration of medical equipment:''' The % of ICU beds in the total hospital beds in China is only 1.8% as compared to 9% in US. It is hard to find an ICU unit in primary level hospitals in China. Only 23.2% of the secondary level hospitals have ICU units. In tertiary level, ICU units are present in 52.5% centers. ''Source: [http://www.criticalcarenews.com/articlePage.aspx?ArticleID=83 ''Critical Care News'']<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="61%" align="center"<br />
|align = "center" bgcolor = "#95B3D7"|'''Country'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of hospital beds per 10,000'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of ICU beds as % of total hospital beds'''<br />
|-<br />
|align = "center"|China<br />
|align = "center"|22<br />
|align = "center"|1.8%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|USA<br />
|align = "center" bgcolor = "#C5D9F1"|31<br />
|align = "center" bgcolor = "#C5D9F1"|9.0%<br />
|-<br />
|align = "center"|France<br />
|align = "center"|73<br />
|align = "center"|2.5%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|UK<br />
|align = "center" bgcolor = "#C5D9F1"|39<br />
|align = "center" bgcolor = "#C5D9F1"|1.2%<br />
|-<br />
|align = "center"|Canada<br />
|align = "center"|34<br />
|align = "center"|3.4%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|Germany<br />
|align = "center" bgcolor = "#C5D9F1"|83<br />
|align = "center" bgcolor = "#C5D9F1"|4.1%<br />
|-<br />
|align = "center"|Netherlands<br />
|align = "center"|84<br />
|align = "center"|2.8%<br />
|-<br />
|}<br />
Source: [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS],[http://www.ncbi.nlm.nih.gov/pubmed/18766102 PubMed Paper]<br />
<br><br />
*'''Government policies and initiatives:''' China put forward plans in 2010 for US$124 billion to be invested in the healthcare reform programme over a three year period until 2012. Hospitals benefit from these reforms leading to faster equipment replacement and and also generating new demand for medical devices. ''Source'': [http://7economy.com/archives/10736 ''7Economy''], [http://www.globalsurance.com/blog/chinas-healthcare-reforms-progress-324520.html ''Globalsurance'']<br />
Based on the above factors the yearly growth rate in number of ICU beds is estimated to be 11.15%.<br />
<br />
==Pricing and Replacements==<br />
*The average price of an ICU ventilator in China is estimated as $ 12,500. In US, the price is between $15,000 - $ 25,000. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The average price of a disposable ICU ventilator circuit in China is estimates as $ 2.5. The price of a disposable ventilator circuit in US is between $4-$5 and that of a reusable circuit is $40-$50. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The number of replacements of disposable circuits in a single year (2011) is estimated to be 80<br />
<br />
==Market Size Calculation==<br />
*The market for ICU Ventilators in China for 2011 is estimated to be $76 Million<br />
*The market for ICU Ventilator Circuits is about $ 12 Million<br />
*Total ICU Ventilators Market is approximately $ 88 Million in China for 2011<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"<br />
|Number of ICU beds in China, 2010<br />
|align = "right"|53,053<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right" bgcolor = "#C5D9F1"|11.5%<br />
|-<br />
|Number of new ICU beds for 2011<br />
|align = "right"|6101<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|6101<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right"|$12,500<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$76,263,837'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total number of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|59,154<br />
|-<br />
|Price of ICU Ventilator Circuit<br />
|align = "right"|$2.5<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of replacements in a year, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|80<br />
|-<br />
|Average cost of Circuits in a year, 2011<br />
|align = "right"|$200<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilator Circuits, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$11,830,842'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total market for ICU Ventilators China, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$88,094,679'''<br />
|-<br />
|}<br />
[[Media:Data Sheet.xlsx]]<br />
<br />
==Methodology Validation==<br />
The Indian ICU Ventilator market (adult) for the year 2009 was valued at $ 39 Million with volume sales of 1,605 units. Source: Expert Inteviews of Leading Players by [http://www.medicalbuyer.co.in/index.php?option=com_content&task=view&id=2652&Itemid=48 Medicalbuyer] <br />
<br />
The figures using our methodology are coming to $ 40 Million with volume sales of 1,674 for the year 2009. This proves the accuracy of our methodology.<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="63%" align="center"<br />
|bgcolor = "#C5D9F1"|Population India, 2008<br />
|align = "right" bgcolor = "#C5D9F1"| 1,147,995,904<br />
|-<br />
|Hospital Beds per 10,000<br />
|align = "right"|9<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"|1,033,196<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.35%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds, 2008<br />
|align = "right" bgcolor = "#C5D9F1"|13,948<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right"|12.0%<br />
|-<br />
|Number of new ICU beds for 2009<br />
|align = "right" bgcolor = "#C5D9F1"|1674<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2009<br />
|align = "right"|'''1674'''<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right" bgcolor = "#C5D9F1"|$24,230<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2009<br />
|align = "right"|'''$40,555,642'''<br />
|-<br />
|}</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=China_ICU_Ventilator_Market&diff=9930China ICU Ventilator Market2011-11-03T10:12:25Z<p>Venkata.reddy: </p>
<hr />
<div>==ICU Ventilators==<br />
Intensive-care Unit (ICU) ventilators offer a wide range of breathing patterns, pressure controls, alarms and sensors. They use compressed oxygen and other gases stored in cylinders, ambient air or a mixture of both. Breathing circuits for these ventilators are double-limbed and can be quite complex. These ventilators are made for bedside use in the intensive-care units of hospitals. The key data provided by the device include:<br />
*Airway pressure (analog bar graph & numerical)<br />
*Total breath rate<br />
*Inspiratory to expiratory time ratio<br />
*Exhaled tidal volume<br />
*Exhaled minute volume<br />
*Peak flow<br />
*Inspiratory time<br />
==Market Assessment Model==<br />
The market data for ICU ventilators in China is not readily available in public domain. There are paid reports published by various market research firms in which the data is either modeled using indicators or collected through primary research methods.<br />
<br />
To arrive at the market size of ICU Ventilators in China for 2011, we have used the following methodology. We have considered only adult ICU Ventilators in this study. <br><br />
[[Image:Methodology1.png|center|700px]]<br />
'''Assumptions''': Each ICU bed will be equipped with one ventilator.<br />
<br />
==Number of ICU Beds==<br />
According to 2010 census, the total population of China is estimated as [http://blogs.wsj.com/indiarealtime/2011/04/30/china-vs-india-the-population-numbers/ 1,339,724,852]. The number of hospital beds in China as per [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS] is 22 per 10,000 population. A research paper on [http://ccforum.com/content/14/1/206 critical care medicine in mainland China] which analyzed many papers including the one from China Critical Care Clinical Trial Group (CCCCTG) estimated the % of ICU beds as total number of hospital beds as 1.8%. <br><br />
{|border="2" cellspacing="0" cellpadding="4" width="53%" align="center"<br />
|bgcolor = "#C5D9F1"|China Population, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|1,339,724,852<br />
|-<br />
|Hospital Beds per 10,000 in China<br />
|align = "right"|22<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"| 2,947,395<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.8%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds in China, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|'''53,053'''<br />
|-<br />
|}<br />
<br />
==Estimate of yearly growth in ICU Beds==<br />
China has taken proactive measures to control the population growth and hence it would not be a relevant indicator for growth in ICU beds. There are several factors to be considered in estimating the growth rate of ICU beds in China.<br><br />
[[Image:growth drivers2.png|center|600px]] <br><br />
*'''Large and ageing population:''' By 2025, the number of people in China aged above 65 years is estimated to reach 198 million. ''Source: US Census Bureau, International Database, July 2003''<br />
* '''Medical device industry growth:''' China medical device market has grown at a CAGR of 13.6% during 2003-2008 from $9 billion to $17 billion. ''Source: Datamonitor Report'' ; The market for Chinese medical devices in 2011 is estimated to be $23.2 billion and has grown at a CAGR of 11.1% during 2006-2011 period.'' Source: Espicom Business Intelligence''<br />
*'''Insufficient ICU beds in hospitals''' & '''Poor penetration of medical equipment:''' The % of ICU beds in the total hospital beds in China is only 1.8% as compared to 9% in US. It is hard to find an ICU unit in primary level hospitals in China. Only 23.2% of the secondary level hospitals have ICU units. In tertiary level, ICU units are present in 52.5% centers. ''Source: [http://www.criticalcarenews.com/articlePage.aspx?ArticleID=83 ''Critical Care News'']<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="61%" align="center"<br />
|align = "center" bgcolor = "#95B3D7"|'''Country'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of hospital beds per 10,000'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of ICU beds as % of total hospital beds'''<br />
|-<br />
|align = "center"|China<br />
|align = "center"|22<br />
|align = "center"|1.8%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|USA<br />
|align = "center" bgcolor = "#C5D9F1"|31<br />
|align = "center" bgcolor = "#C5D9F1"|9.0%<br />
|-<br />
|align = "center"|France<br />
|align = "center"|73<br />
|align = "center"|2.5%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|UK<br />
|align = "center" bgcolor = "#C5D9F1"|39<br />
|align = "center" bgcolor = "#C5D9F1"|1.2%<br />
|-<br />
|align = "center"|Canada<br />
|align = "center"|34<br />
|align = "center"|3.4%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|Germany<br />
|align = "center" bgcolor = "#C5D9F1"|83<br />
|align = "center" bgcolor = "#C5D9F1"|4.1%<br />
|-<br />
|align = "center"|Netherlands<br />
|align = "center"|84<br />
|align = "center"|2.8%<br />
|-<br />
|}<br />
Source: [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS],[http://www.ncbi.nlm.nih.gov/pubmed/18766102 PubMed Paper]<br />
<br><br />
*'''Government policies and initiatives:''' China put forward plans in 2010 for US$124 billion to be invested in the healthcare reform programme over a three year period until 2012. Hospitals benefit from these reforms leading to faster equipment replacement and and also generating new demand for medical devices. ''Source'': [http://7economy.com/archives/10736 ''7Economy''], [http://www.globalsurance.com/blog/chinas-healthcare-reforms-progress-324520.html ''Globalsurance'']<br />
Based on the above factors the yearly growth rate in number of ICU beds is estimated to be 11.15%.<br />
<br />
==Pricing and Replacements==<br />
*The average price of an ICU ventilator in China is estimated as $ 12,500. In US, the price is between $15,000 - $ 25,000. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The average price of a disposable ICU ventilator circuit in China is estimates as $ 2.5. The price of a disposable ventilator circuit in US is between $4-$5 and that of a reusable circuit is $40-$50. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The number of replacements of disposable circuits in a single year (2011) is estimated to be 80<br />
<br />
==Market Size Calculation==<br />
*The market for ICU Ventilators in China for 2011 is estimated to be $76 Million<br />
*The market for ICU Ventilator Circuits is about $ 12 Million<br />
*Total ICU Ventilators Market is approximately $ 88 Million in China for 2011<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"<br />
|Number of ICU beds in China, 2010<br />
|align = "right"|53,053<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right" bgcolor = "#C5D9F1"|11.5%<br />
|-<br />
|Number of new ICU beds for 2011<br />
|align = "right"|6101<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|6101<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right"|$12,500<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$76,263,837'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total number of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|59,154<br />
|-<br />
|Price of ICU Ventilator Circuit<br />
|align = "right"|$2.5<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of replacements in a year, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|80<br />
|-<br />
|Average cost of Circuits in a year, 2011<br />
|align = "right"|$200<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilator Circuits, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$11,830,842'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total market for ICU Ventilators China, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$88,094,679'''<br />
|-<br />
|}<br />
[[Media:ICU Ventilator Market China - Work Sheet.xlsx]]<br />
==Methodology Validation==<br />
The Indian ICU Ventilator market (adult) for the year 2009 was valued at $ 39 Million with volume sales of 1,605 units. Source: Expert Inteviews of Leading Players by [http://www.medicalbuyer.co.in/index.php?option=com_content&task=view&id=2652&Itemid=48 Medicalbuyer] <br />
<br />
The figures using our methodology are coming to $ 40 Million with volume sales of 1,674 for the year 2009. This proves the accuracy of our methodology.<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="63%" align="center"<br />
|bgcolor = "#C5D9F1"|Population India, 2008<br />
|align = "right" bgcolor = "#C5D9F1"| 1,147,995,904<br />
|-<br />
|Hospital Beds per 10,000<br />
|align = "right"|9<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"|1,033,196<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.35%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds, 2008<br />
|align = "right" bgcolor = "#C5D9F1"|13,948<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right"|12.0%<br />
|-<br />
|Number of new ICU beds for 2009<br />
|align = "right" bgcolor = "#C5D9F1"|1674<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2009<br />
|align = "right"|'''1674'''<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right" bgcolor = "#C5D9F1"|$24,230<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2009<br />
|align = "right"|'''$40,555,642'''<br />
|-<br />
|}</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Olympus_Corporation-_Company_Profile&diff=9737Olympus Corporation- Company Profile2011-09-20T08:13:17Z<p>Venkata.reddy: /* Recent Developments */</p>
<hr />
<div>==Company overview==<br />
<br />
OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments. <br />
* '''Medical Systems:''' Manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes<br />
* '''Life and Industrial:''' Provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment<br />
* '''Imaging:''' Manufacture and sale of digital cameras and voice recorders<br />
* '''Information Communication:''' Sale of mobile terminals, such as cellular phones <br />
* '''Others:''' Development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems<br />
<br />
<br><br />
In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary.<br><br />
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.<br />
<br />
===Key Facts===<br />
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"<br />
|bgcolor = "#DBE5F1"|'''Established'''<br />
|1919<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Headquarters'''<br />
|Tokyo, Japan<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Type'''<br />
|Public Company<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Website'''<br />
|[http://www.olympus-global.com/en/ www.olympus-global.com]<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Regional involvement'''<br />
|Worldwide<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Business lines'''<br />
|Manufacture and Sales of precision machinery and instruments <br />
|-<br />
|bgcolor = "#DBE5F1"|'''Employees'''<br />
|34,391<br> Medical System Business: 15,000 Approx.<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Group Companies'''<br />
|Approx. 180 Subsidiaries<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''<br />
|Tsuyoshi Kikukawa<br />
|-<br />
|bgcolor = "#DBE5F1"|'''President & COO'''<br />
|Michael C. Woodford<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Consolidated Net Sales (2011)'''<br />
|847.1 Billion YEN<br />
|}<br />
<br><br />
<br />
===Key Financials===<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Olympus Corporation'''</font><br />
|bgcolor = "#4F81BD"|<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Financial Year End'''<br />
|bgcolor = "#DBE5F1"|March, 31st<br />
|-<br />
|align = "center" rowspan = "2"|'''Revenue'''<br />
|2011: ¥847.10B / $10.58B<br />
|-<br />
|2010: ¥ 883.08B / $11.03B<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Revenue Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>4.07%<br />
|-<br />
|align = "center" rowspan = "2"|'''Operating Income'''<br />
|2011: ¥35.4 B / $442M<br />
|-<br />
|2010: ¥60.1B / $751M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>41.10%<br />
|-<br />
|align = "center" rowspan = "2"|'''Net Profit'''<br />
|2011: ¥7.38B / $92.25M<br />
|-<br />
|2010: ¥47.76B / $597M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>84.45%<br />
|-<br />
|align = "center" rowspan = "2"|'''R&D Expenses'''<br />
|2011: ¥67.28B / $841M<br />
|-<br />
|2010: ¥61.85B / $773M<br />
|-<br />
|}<br />
<br><br />
<br />
===Revenue Distribution===<br />
{|align="center" <br />
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash><br />
|-<br />
|}<br />
<br><br />
Source: SEC fillings<br />
<br />
==Business Overview==<br />
<br />
===Business lines===<br />
The company operates under the following business lines:<br />
<br />
[[Image:Business_lines.PNG|centre]]<br />
<br />
<br />
<br />
<br />
===Organisation Structure===<br />
<br />
[[Image:OrgChart_Oympus.png|centre]]<br />
<br><br />
<br />
In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.<br />
<br />
==Medical Systems Business==<br />
<br />
The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.<br />
<br><br />
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment. <br />
<br><br />
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.<br />
<br><br />
<br />
Medical systems business has the following business lines:<br />
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products<br />
* '''MIP''' includes surgical endoscopes and treatment equipments<br />
** '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals<br />
** '''Endotherapy''' <br>Endotherapy products<br />
<br />
<br />
<br />
===Revenue===<br />
Medical systems business is the biggest business segment of Olympus corporation:<br />
* Net sales ratio : 40% approx.<br />
* Contribution to total corporate operating income :109% approx. <br />
:(before corporate allocation of expenses)<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="81%" align="center"<br />
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font><br />
|bgcolor = "#376091"|<font color="#FFFFFF">''' '''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|align = "left" bgcolor = "#95B3D7" rowspan = "3"|'''Medical Systems'''<br />
|'''Domestic'''<br />
|align = "right"|76.2<br />
|align = "right"|75.1<br />
|align = "right"|79.4<br />
|-<br />
|'''Overseas'''<br />
|align = "right"|307.6<br />
|align = "right"|275.7<br />
|align = "right"|275.9<br />
|-<br />
|bgcolor = "#95B3D7"|'''Total'''<br />
|align = "right" bgcolor = "#95B3D7"|'''383.89'''<br />
|align = "right" bgcolor = "#95B3D7"|'''350.75'''<br />
|align = "right" bgcolor = "#95B3D7"|'''355.46'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|Endoscopes<br />
|align = "center"|Domestic<br />
|align = "right"|44.6<br />
|align = "right"|40.9<br />
|align = "right"|43.8<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|168.3<br />
|align = "right"|151<br />
|align = "right"|151.6<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''212.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''191.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''195.5'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|MIP<br />
|align = "center"|Domestic<br />
|align = "right"|31.6<br />
|align = "right"|34.2<br />
|align = "right"|35.6<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|139.3<br />
|align = "right"|124.6<br />
|align = "right"|124.3<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''170.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''158.8'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''159.9'''<br />
|-<br />
|}<br />
<br><br />
<br />
===Projections for FY 2012===<br />
Quarter 3<br />
<br><br />
<br />
* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.<br />
* The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.<br />
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).<br />
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.<br />
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.<br />
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.<br />
<br><br />
<br />
===Geographic Presence===<br />
[[Image:Geo_olympus.PNG|center|1000px|thumb| Source: [http://www.olympus-global.com/ Olympus]]]<br />
<br><br />
<br />
===Corporate Strategic Plan===<br />
* Expand the endoscopic business base ( Gastrointestinal )<br />
** Gain a dominant market share and ensure profitability in the imaging field<br />
*** Early introduction and diffusion of next generation endoscope systems<br />
*** Establishment of a significant presence in emerging markets<br />
*** Diagnostic technology to promote early detection<br />
*** Endoscope technology to achieve definite diagnoses<br />
** Imaging technology for achieving early detection :Narrow Band Imaging (NBI)<br />
*** Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)<br />
*** Initiative for standardization of NBI observation as diagnosis<br />
* Growth Drivers<br />
** Expansion of EndoTherapy field<br />
*** Introduce Visera Elite, a new integrated endoscopy video system<br />
*** Secure a 30% share of the global operating room imaging market in 2015<br />
*** Expand the lineup of differentiated products focused on minimally invasive surgical techniques<br />
*** Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure<br />
** Expansion of Chinese and Asian market<br />
*** Introduce popularly prices models<br />
*** Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.<br />
<br />
==Endoscopes Business==<br />
<br />
<br />
<br />
===Market Share===<br />
<br />
[[Image:CoSHare1.PNG|centre|frame|Source: Espicom]]<br />
<br><br />
The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology<br />
products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately '''US$21.3 billion in 2009'''. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an<br />
approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith &<br />
Nephew (4%) and Karl Storz (4%).<br />
<br />
===Product Portfolio===<br />
<br />
[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]<br />
<br><br />
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.<br />
<br><br />
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.<br />
<br />
<br />
===Recent Developments===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No'''</font><br />
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Date'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font><br />
|-<br />
|align = "center"|1<br />
|align = "center"|July 2011<br />
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]<br />
|-<br />
|align = "center"|2<br />
|align = "center"|May 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]<br />
|-<br />
|align = "center"|3<br />
|align = "center"|May 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]<br />
|-<br />
|align = "center"|4<br />
|align = "center"|April 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]<br />
|-<br />
|align = "center"|5<br />
|align = "center"|February 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]<br />
|-<br />
|align = "center"|6<br />
|align = "center"|October 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]<br />
|-<br />
|align = "center"|7<br />
|align = "center"|May 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]<br />
|-<br />
|align = "center"|8<br />
|align = "center"|April 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]<br />
|-<br />
|align = "center"|9<br />
|align = "center"|April 2010<br />
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]<br />
|-<br />
|align = "center"|10<br />
|align = "center"|February 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]<br />
|-<br />
|align = "center"|11<br />
|align = "center"|November 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]<br />
|-<br />
|align = "center"|12<br />
|align = "center"|October 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]<br />
|-<br />
|align = "center"|13<br />
|align = "center"|February 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]<br />
|-<br />
|align = "center"|14<br />
|align = "center"|December 2008<br />
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]<br />
|-<br />
|align = "center"|15<br />
|align = "center"|November 2008<br />
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]<br />
|-<br />
|}<br />
<br><br />
<br />
==Gastrointestinal Endoscopes Business==<br />
<br />
With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs<br />
<br><br />
<br />
===Diagnosis and Treatment using Gastrointestinal Endoscopy===<br />
<br />
'''Diagnosis'''<br />
* Biopsy<br />
* Cytodiagnosis<br />
* Staining<br />
<br><br />
'''Treatment'''<br />
* Cancer (esophageal, stomach, colon, etc.)<br />
* Varcies (esophageal)<br />
* Foreign object retrieval ( esophagus, stomach) <br />
* Hemostasis (stomach)<br />
* Ployps (stomach, colon)<br />
* Gallstones, bile duct stenosis (duodenum)<br />
<br />
===Market Share===<br />
[[Image:GIshare.PNG|center|frame|Source: Espicom]]<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company ( in Billion Yen)'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2009'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2010'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|bgcolor = "#DBE5F1"|Olympus<br />
|align = "right"| 212.89<br />
|align = "right"| 191.94 <br />
|align = "right"| 195.45 <br />
|-<br />
|bgcolor = "#DBE5F1"|FujiFilm HD<br />
|align = "right"| 26.98<br />
|align = "right"| 25.00 <br />
|align = "right"| 27.00<br />
|-<br />
|bgcolor = "#DBE5F1"|Hoya<br />
|align = "right"| 48.87 <br />
|align = "right"| 47.00 <br />
|align = "right"| 45.00 <br />
|-<br />
|}<br />
<br />
===Products Offered===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Speciality'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Details'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Picture'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Products'''</font><br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Gastroscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the interior of the stomach.<br />
|[[Image:Gastroscope2.PNG|120px]] [[Image:Gastroscope.PNG|120px]] [[Image:Gastroscope1.PNG|120px]]<br />
|<br />
* GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus<br />
* GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality<br />
* GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube<br />
* GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced. <br />
* GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.<br />
* GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view<br />
* GIF-2T160: Two-channel endoscope for a variety of therapeutic applications<br />
* GIF-XTQ160: Endoscope with powerful suction capabilities<br />
* GIF-1TQ160: Endoscope with extended instrumentation capabilities<br />
* GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Duodenoscopy''' <br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the duodenum<br />
|[[Image:TJF-Q180V.PNG|100px]] [[Image:TJF-160VR.PNG|100px]]<br />
|<br />
* TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function sets a new standard for ease-of-use and security during instrument exchange.<br />
* TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices<br />
* TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.<br />
* JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Colonoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the colon.<br />
|[[Image:CF-180AI.PNG|100px]] [[Image:CQ-180AI.PNG|100px]] [[Image:CF-Q160DI.PNG|100px]]<br />
|<br />
* CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.<br />
* PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics<br />
* CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.<br />
* CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.<br />
* CF-2T160I/L: Two-channel therapeutic capabilities<br />
* CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation. Powerful 150 times zoom magnification delivers detailed close-ups<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Proctoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the rectum.<br />
|[[Image:Procto.PNG|100px]]<br />
|<br />
* Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.<br />
* Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard VISERA equipment.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Enteroscopy'''<br />
|bgcolor = "#DBE5F1"|Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach<br />
|[[Image:Enteroscope1.png|100px]] [[Image:Enteroscope2.png|100px]]<br />
|<br />
* QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel<br />
* Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel. <br />
* BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation<br />
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis<br />
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.<br />
|-<br />
|}<br />
<br><br />
Source: Company website<br />
<br />
===New Products===<br />
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.<br />
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.<br />
* '''Capsule Endoscopes:'''<br> [[Image:Capsule.png|right|120px]] They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy.<br> One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities.<br>The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach.<br>Product Details:[[Image:Capsule1.png|right|140px]]<br />
** Supersensitive CCD <br />
** Ultra compact lens <br />
** Automatic Brightness Control adjusts illumination to maintain optimal imaging <br />
** A wide depth of field provides superior observation <br />
** 6 white LED lights always ensure a clear field of view <br />
** Compact battery with energy efficient technology<br />
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.<br />
<br><br />
Source: Company website, SEC fillings</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Olympus_Corporation-_Company_Profile&diff=9736Olympus Corporation- Company Profile2011-09-20T08:09:26Z<p>Venkata.reddy: /* Revenue */</p>
<hr />
<div>==Company overview==<br />
<br />
OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments. <br />
* '''Medical Systems:''' Manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes<br />
* '''Life and Industrial:''' Provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment<br />
* '''Imaging:''' Manufacture and sale of digital cameras and voice recorders<br />
* '''Information Communication:''' Sale of mobile terminals, such as cellular phones <br />
* '''Others:''' Development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems<br />
<br />
<br><br />
In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary.<br><br />
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.<br />
<br />
===Key Facts===<br />
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"<br />
|bgcolor = "#DBE5F1"|'''Established'''<br />
|1919<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Headquarters'''<br />
|Tokyo, Japan<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Type'''<br />
|Public Company<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Website'''<br />
|[http://www.olympus-global.com/en/ www.olympus-global.com]<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Regional involvement'''<br />
|Worldwide<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Business lines'''<br />
|Manufacture and Sales of precision machinery and instruments <br />
|-<br />
|bgcolor = "#DBE5F1"|'''Employees'''<br />
|34,391<br> Medical System Business: 15,000 Approx.<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Group Companies'''<br />
|Approx. 180 Subsidiaries<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''<br />
|Tsuyoshi Kikukawa<br />
|-<br />
|bgcolor = "#DBE5F1"|'''President & COO'''<br />
|Michael C. Woodford<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Consolidated Net Sales (2011)'''<br />
|847.1 Billion YEN<br />
|}<br />
<br><br />
<br />
===Key Financials===<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Olympus Corporation'''</font><br />
|bgcolor = "#4F81BD"|<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Financial Year End'''<br />
|bgcolor = "#DBE5F1"|March, 31st<br />
|-<br />
|align = "center" rowspan = "2"|'''Revenue'''<br />
|2011: ¥847.10B / $10.58B<br />
|-<br />
|2010: ¥ 883.08B / $11.03B<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Revenue Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>4.07%<br />
|-<br />
|align = "center" rowspan = "2"|'''Operating Income'''<br />
|2011: ¥35.4 B / $442M<br />
|-<br />
|2010: ¥60.1B / $751M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>41.10%<br />
|-<br />
|align = "center" rowspan = "2"|'''Net Profit'''<br />
|2011: ¥7.38B / $92.25M<br />
|-<br />
|2010: ¥47.76B / $597M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>84.45%<br />
|-<br />
|align = "center" rowspan = "2"|'''R&D Expenses'''<br />
|2011: ¥67.28B / $841M<br />
|-<br />
|2010: ¥61.85B / $773M<br />
|-<br />
|}<br />
<br><br />
<br />
===Revenue Distribution===<br />
{|align="center" <br />
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash><br />
|-<br />
|}<br />
<br><br />
Source: SEC fillings<br />
<br />
==Business Overview==<br />
<br />
===Business lines===<br />
The company operates under the following business lines:<br />
<br />
[[Image:Business_lines.PNG|centre]]<br />
<br />
<br />
<br />
<br />
===Organisation Structure===<br />
<br />
[[Image:OrgChart_Oympus.png|centre]]<br />
<br><br />
<br />
In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.<br />
<br />
==Medical Systems Business==<br />
<br />
The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.<br />
<br><br />
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment. <br />
<br><br />
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.<br />
<br><br />
<br />
Medical systems business has the following business lines:<br />
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products<br />
* '''MIP''' includes surgical endoscopes and treatment equipments<br />
** '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals<br />
** '''Endotherapy''' <br>Endotherapy products<br />
<br />
<br />
<br />
===Revenue===<br />
Medical systems business is the biggest business segment of Olympus corporation:<br />
* Net sales ratio : 40% approx.<br />
* Contribution to total corporate operating income :109% approx. <br />
:(before corporate allocation of expenses)<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="81%" align="center"<br />
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font><br />
|bgcolor = "#376091"|<font color="#FFFFFF">''' '''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|align = "left" bgcolor = "#95B3D7" rowspan = "3"|'''Medical Systems'''<br />
|'''Domestic'''<br />
|align = "right"|76.2<br />
|align = "right"|75.1<br />
|align = "right"|79.4<br />
|-<br />
|'''Overseas'''<br />
|align = "right"|307.6<br />
|align = "right"|275.7<br />
|align = "right"|275.9<br />
|-<br />
|bgcolor = "#95B3D7"|'''Total'''<br />
|align = "right" bgcolor = "#95B3D7"|'''383.89'''<br />
|align = "right" bgcolor = "#95B3D7"|'''350.75'''<br />
|align = "right" bgcolor = "#95B3D7"|'''355.46'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|Endoscopes<br />
|align = "center"|Domestic<br />
|align = "right"|44.6<br />
|align = "right"|40.9<br />
|align = "right"|43.8<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|168.3<br />
|align = "right"|151<br />
|align = "right"|151.6<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''212.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''191.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''195.5'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|MIP<br />
|align = "center"|Domestic<br />
|align = "right"|31.6<br />
|align = "right"|34.2<br />
|align = "right"|35.6<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|139.3<br />
|align = "right"|124.6<br />
|align = "right"|124.3<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''170.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''158.8'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''159.9'''<br />
|-<br />
|}<br />
<br><br />
<br />
===Projections for FY 2012===<br />
Quarter 3<br />
<br><br />
<br />
* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.<br />
* The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.<br />
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).<br />
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.<br />
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.<br />
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.<br />
<br><br />
<br />
===Geographic Presence===<br />
[[Image:Geo_olympus.PNG|center|1000px|thumb| Source: [http://www.olympus-global.com/ Olympus]]]<br />
<br><br />
<br />
===Corporate Strategic Plan===<br />
* Expand the endoscopic business base ( Gastrointestinal )<br />
** Gain a dominant market share and ensure profitability in the imaging field<br />
*** Early introduction and diffusion of next generation endoscope systems<br />
*** Establishment of a significant presence in emerging markets<br />
*** Diagnostic technology to promote early detection<br />
*** Endoscope technology to achieve definite diagnoses<br />
** Imaging technology for achieving early detection :Narrow Band Imaging (NBI)<br />
*** Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)<br />
*** Initiative for standardization of NBI observation as diagnosis<br />
* Growth Drivers<br />
** Expansion of EndoTherapy field<br />
*** Introduce Visera Elite, a new integrated endoscopy video system<br />
*** Secure a 30% share of the global operating room imaging market in 2015<br />
*** Expand the lineup of differentiated products focused on minimally invasive surgical techniques<br />
*** Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure<br />
** Expansion of Chinese and Asian market<br />
*** Introduce popularly prices models<br />
*** Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.<br />
<br />
==Endoscopes Business==<br />
<br />
<br />
<br />
===Market Share===<br />
<br />
[[Image:CoSHare1.PNG|centre|frame|Source: Espicom]]<br />
<br><br />
The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology<br />
products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately '''US$21.3 billion in 2009'''. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an<br />
approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith &<br />
Nephew (4%) and Karl Storz (4%).<br />
<br />
===Product Portfolio===<br />
<br />
[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]<br />
<br><br />
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.<br />
<br><br />
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.<br />
<br />
<br />
===Recent Developments===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Date'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font><br />
|-<br />
|align = "right"|1.<br />
|July 2011<br />
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]<br />
|-<br />
|align = "right"|2.<br />
|May 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]<br />
|-<br />
|align = "right"|3.<br />
|May 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]<br />
|-<br />
|align = "right"|4.<br />
|April 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]<br />
|-<br />
|align = "right"|5.<br />
|February 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]<br />
|-<br />
|align = "right"|6.<br />
|October 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]<br />
|-<br />
|align = "right"|7.<br />
|May 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]<br />
|-<br />
|align = "right"|8.<br />
|April 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]<br />
|-<br />
|align = "right"|9.<br />
|April 2010<br />
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]<br />
|-<br />
|align = "right"|10.<br />
|February 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]<br />
|-<br />
|align = "right"|11.<br />
|November 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]<br />
|-<br />
|align = "right"|12.<br />
|October 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]<br />
|-<br />
|align = "right"|13.<br />
|February 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]<br />
|-<br />
|align = "right"|14.<br />
|December 2008<br />
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]<br />
|-<br />
|align = "right"|15.<br />
|November 2008<br />
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]<br />
|-<br />
|}<br />
<br><br />
<br />
==Gastrointestinal Endoscopes Business==<br />
<br />
With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs<br />
<br><br />
<br />
===Diagnosis and Treatment using Gastrointestinal Endoscopy===<br />
<br />
'''Diagnosis'''<br />
* Biopsy<br />
* Cytodiagnosis<br />
* Staining<br />
<br><br />
'''Treatment'''<br />
* Cancer (esophageal, stomach, colon, etc.)<br />
* Varcies (esophageal)<br />
* Foreign object retrieval ( esophagus, stomach) <br />
* Hemostasis (stomach)<br />
* Ployps (stomach, colon)<br />
* Gallstones, bile duct stenosis (duodenum)<br />
<br />
===Market Share===<br />
[[Image:GIshare.PNG|center|frame|Source: Espicom]]<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company ( in Billion Yen)'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2009'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2010'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|bgcolor = "#DBE5F1"|Olympus<br />
|align = "right"| 212.89<br />
|align = "right"| 191.94 <br />
|align = "right"| 195.45 <br />
|-<br />
|bgcolor = "#DBE5F1"|FujiFilm HD<br />
|align = "right"| 26.98<br />
|align = "right"| 25.00 <br />
|align = "right"| 27.00<br />
|-<br />
|bgcolor = "#DBE5F1"|Hoya<br />
|align = "right"| 48.87 <br />
|align = "right"| 47.00 <br />
|align = "right"| 45.00 <br />
|-<br />
|}<br />
<br />
===Products Offered===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Speciality'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Details'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Picture'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Products'''</font><br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Gastroscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the interior of the stomach.<br />
|[[Image:Gastroscope2.PNG|120px]] [[Image:Gastroscope.PNG|120px]] [[Image:Gastroscope1.PNG|120px]]<br />
|<br />
* GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus<br />
* GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality<br />
* GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube<br />
* GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced. <br />
* GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.<br />
* GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view<br />
* GIF-2T160: Two-channel endoscope for a variety of therapeutic applications<br />
* GIF-XTQ160: Endoscope with powerful suction capabilities<br />
* GIF-1TQ160: Endoscope with extended instrumentation capabilities<br />
* GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Duodenoscopy''' <br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the duodenum<br />
|[[Image:TJF-Q180V.PNG|100px]] [[Image:TJF-160VR.PNG|100px]]<br />
|<br />
* TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function sets a new standard for ease-of-use and security during instrument exchange.<br />
* TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices<br />
* TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.<br />
* JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Colonoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the colon.<br />
|[[Image:CF-180AI.PNG|100px]] [[Image:CQ-180AI.PNG|100px]] [[Image:CF-Q160DI.PNG|100px]]<br />
|<br />
* CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.<br />
* PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics<br />
* CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.<br />
* CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.<br />
* CF-2T160I/L: Two-channel therapeutic capabilities<br />
* CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation. Powerful 150 times zoom magnification delivers detailed close-ups<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Proctoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the rectum.<br />
|[[Image:Procto.PNG|100px]]<br />
|<br />
* Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.<br />
* Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard VISERA equipment.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Enteroscopy'''<br />
|bgcolor = "#DBE5F1"|Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach<br />
|[[Image:Enteroscope1.png|100px]] [[Image:Enteroscope2.png|100px]]<br />
|<br />
* QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel<br />
* Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel. <br />
* BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation<br />
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis<br />
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.<br />
|-<br />
|}<br />
<br><br />
Source: Company website<br />
<br />
===New Products===<br />
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.<br />
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.<br />
* '''Capsule Endoscopes:'''<br> [[Image:Capsule.png|right|120px]] They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy.<br> One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities.<br>The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach.<br>Product Details:[[Image:Capsule1.png|right|140px]]<br />
** Supersensitive CCD <br />
** Ultra compact lens <br />
** Automatic Brightness Control adjusts illumination to maintain optimal imaging <br />
** A wide depth of field provides superior observation <br />
** 6 white LED lights always ensure a clear field of view <br />
** Compact battery with energy efficient technology<br />
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.<br />
<br><br />
Source: Company website, SEC fillings</div>Venkata.reddyhttps://www.dolcera.com/wiki/index.php?title=Olympus_Corporation-_Company_Profile&diff=9735Olympus Corporation- Company Profile2011-09-20T08:08:45Z<p>Venkata.reddy: /* Employee Distribution */</p>
<hr />
<div>==Company overview==<br />
<br />
OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments. <br />
* '''Medical Systems:''' Manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes<br />
* '''Life and Industrial:''' Provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment<br />
* '''Imaging:''' Manufacture and sale of digital cameras and voice recorders<br />
* '''Information Communication:''' Sale of mobile terminals, such as cellular phones <br />
* '''Others:''' Development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems<br />
<br />
<br><br />
In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary.<br><br />
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.<br />
<br />
===Key Facts===<br />
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"<br />
|bgcolor = "#DBE5F1"|'''Established'''<br />
|1919<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Headquarters'''<br />
|Tokyo, Japan<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Type'''<br />
|Public Company<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Website'''<br />
|[http://www.olympus-global.com/en/ www.olympus-global.com]<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Regional involvement'''<br />
|Worldwide<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Business lines'''<br />
|Manufacture and Sales of precision machinery and instruments <br />
|-<br />
|bgcolor = "#DBE5F1"|'''Employees'''<br />
|34,391<br> Medical System Business: 15,000 Approx.<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Group Companies'''<br />
|Approx. 180 Subsidiaries<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''<br />
|Tsuyoshi Kikukawa<br />
|-<br />
|bgcolor = "#DBE5F1"|'''President & COO'''<br />
|Michael C. Woodford<br />
|-<br />
|bgcolor = "#DBE5F1"|'''Consolidated Net Sales (2011)'''<br />
|847.1 Billion YEN<br />
|}<br />
<br><br />
<br />
===Key Financials===<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="71%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Olympus Corporation'''</font><br />
|bgcolor = "#4F81BD"|<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Financial Year End'''<br />
|bgcolor = "#DBE5F1"|March, 31st<br />
|-<br />
|align = "center" rowspan = "2"|'''Revenue'''<br />
|2011: ¥847.10B / $10.58B<br />
|-<br />
|2010: ¥ 883.08B / $11.03B<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Revenue Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>4.07%<br />
|-<br />
|align = "center" rowspan = "2"|'''Operating Income'''<br />
|2011: ¥35.4 B / $442M<br />
|-<br />
|2010: ¥60.1B / $751M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>41.10%<br />
|-<br />
|align = "center" rowspan = "2"|'''Net Profit'''<br />
|2011: ¥7.38B / $92.25M<br />
|-<br />
|2010: ¥47.76B / $597M<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change<br />
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>84.45%<br />
|-<br />
|align = "center" rowspan = "2"|'''R&D Expenses'''<br />
|2011: ¥67.28B / $841M<br />
|-<br />
|2010: ¥61.85B / $773M<br />
|-<br />
|}<br />
<br><br />
<br />
===Revenue Distribution===<br />
{|align="center" <br />
|<gflash>1100 825 http://dolcera.com/upload/files/Revenue_Metrics.swf</gflash><br />
|-<br />
|}<br />
<br><br />
Source: SEC fillings<br />
<br />
==Business Overview==<br />
<br />
===Business lines===<br />
The company operates under the following business lines:<br />
<br />
[[Image:Business_lines.PNG|centre]]<br />
<br />
<br />
<br />
<br />
===Organisation Structure===<br />
<br />
[[Image:OrgChart_Oympus.png|centre]]<br />
<br><br />
<br />
In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.<br />
<br />
==Medical Systems Business==<br />
<br />
The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.<br />
<br><br />
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment. <br />
<br><br />
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.<br />
<br><br />
<br />
Medical systems business has the following business lines:<br />
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products<br />
* '''MIP''' includes surgical endoscopes and treatment equipments<br />
** '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals<br />
** '''Endotherapy''' <br>Endotherapy products<br />
<br />
<br />
<br />
===Revenue===<br />
Medical systems business is the biggest business segment of Olympus corporation:<br />
* Net sales ratio : 40% approx.<br />
* Contribution to total corporate operating income :109% approx. <br />
:(before corporate allocation of expenses)<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="81%"<br />
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font><br />
|bgcolor = "#376091"|<font color="#FFFFFF">''' '''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font><br />
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|align = "left" bgcolor = "#95B3D7" rowspan = "3"|'''Medical Systems'''<br />
|'''Domestic'''<br />
|align = "right"|76.2<br />
|align = "right"|75.1<br />
|align = "right"|79.4<br />
|-<br />
|'''Overseas'''<br />
|align = "right"|307.6<br />
|align = "right"|275.7<br />
|align = "right"|275.9<br />
|-<br />
|bgcolor = "#95B3D7"|'''Total'''<br />
|align = "right" bgcolor = "#95B3D7"|'''383.89'''<br />
|align = "right" bgcolor = "#95B3D7"|'''350.75'''<br />
|align = "right" bgcolor = "#95B3D7"|'''355.46'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|Endoscopes<br />
|align = "center"|Domestic<br />
|align = "right"|44.6<br />
|align = "right"|40.9<br />
|align = "right"|43.8<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|168.3<br />
|align = "right"|151<br />
|align = "right"|151.6<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''212.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''191.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''195.5'''<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|MIP<br />
|align = "center"|Domestic<br />
|align = "right"|31.6<br />
|align = "right"|34.2<br />
|align = "right"|35.6<br />
|-<br />
|align = "center"|Overseas<br />
|align = "right"|139.3<br />
|align = "right"|124.6<br />
|align = "right"|124.3<br />
|-<br />
|align = "center" bgcolor = "#DBE5F1"|'''Total'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''170.9'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''158.8'''<br />
|align = "right" bgcolor = "#DBE5F1"|'''159.9'''<br />
|-<br />
|}<br />
<br><br />
<br />
===Projections for FY 2012===<br />
Quarter 3<br />
<br><br />
<br />
* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.<br />
* The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.<br />
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).<br />
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.<br />
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.<br />
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.<br />
<br><br />
<br />
===Geographic Presence===<br />
[[Image:Geo_olympus.PNG|center|1000px|thumb| Source: [http://www.olympus-global.com/ Olympus]]]<br />
<br><br />
<br />
===Corporate Strategic Plan===<br />
* Expand the endoscopic business base ( Gastrointestinal )<br />
** Gain a dominant market share and ensure profitability in the imaging field<br />
*** Early introduction and diffusion of next generation endoscope systems<br />
*** Establishment of a significant presence in emerging markets<br />
*** Diagnostic technology to promote early detection<br />
*** Endoscope technology to achieve definite diagnoses<br />
** Imaging technology for achieving early detection :Narrow Band Imaging (NBI)<br />
*** Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)<br />
*** Initiative for standardization of NBI observation as diagnosis<br />
* Growth Drivers<br />
** Expansion of EndoTherapy field<br />
*** Introduce Visera Elite, a new integrated endoscopy video system<br />
*** Secure a 30% share of the global operating room imaging market in 2015<br />
*** Expand the lineup of differentiated products focused on minimally invasive surgical techniques<br />
*** Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure<br />
** Expansion of Chinese and Asian market<br />
*** Introduce popularly prices models<br />
*** Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.<br />
<br />
==Endoscopes Business==<br />
<br />
<br />
<br />
===Market Share===<br />
<br />
[[Image:CoSHare1.PNG|centre|frame|Source: Espicom]]<br />
<br><br />
The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology<br />
products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately '''US$21.3 billion in 2009'''. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an<br />
approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith &<br />
Nephew (4%) and Karl Storz (4%).<br />
<br />
===Product Portfolio===<br />
<br />
[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]<br />
<br><br />
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.<br />
<br><br />
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.<br />
<br />
<br />
===Recent Developments===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Date'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font><br />
|-<br />
|align = "right"|1.<br />
|July 2011<br />
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]<br />
|-<br />
|align = "right"|2.<br />
|May 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]<br />
|-<br />
|align = "right"|3.<br />
|May 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]<br />
|-<br />
|align = "right"|4.<br />
|April 2011<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]<br />
|-<br />
|align = "right"|5.<br />
|February 2011<br />
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]<br />
|-<br />
|align = "right"|6.<br />
|October 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]<br />
|-<br />
|align = "right"|7.<br />
|May 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]<br />
|-<br />
|align = "right"|8.<br />
|April 2010<br />
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]<br />
|-<br />
|align = "right"|9.<br />
|April 2010<br />
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]<br />
|-<br />
|align = "right"|10.<br />
|February 2010<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]<br />
|-<br />
|align = "right"|11.<br />
|November 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]<br />
|-<br />
|align = "right"|12.<br />
|October 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]<br />
|-<br />
|align = "right"|13.<br />
|February 2009<br />
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]<br />
|-<br />
|align = "right"|14.<br />
|December 2008<br />
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]<br />
|-<br />
|align = "right"|15.<br />
|November 2008<br />
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]<br />
|-<br />
|}<br />
<br><br />
<br />
==Gastrointestinal Endoscopes Business==<br />
<br />
With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs<br />
<br><br />
<br />
===Diagnosis and Treatment using Gastrointestinal Endoscopy===<br />
<br />
'''Diagnosis'''<br />
* Biopsy<br />
* Cytodiagnosis<br />
* Staining<br />
<br><br />
'''Treatment'''<br />
* Cancer (esophageal, stomach, colon, etc.)<br />
* Varcies (esophageal)<br />
* Foreign object retrieval ( esophagus, stomach) <br />
* Hemostasis (stomach)<br />
* Ployps (stomach, colon)<br />
* Gallstones, bile duct stenosis (duodenum)<br />
<br />
===Market Share===<br />
[[Image:GIshare.PNG|center|frame|Source: Espicom]]<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"<br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company ( in Billion Yen)'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2009'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2010'''</font><br />
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2011'''</font><br />
|-<br />
|bgcolor = "#DBE5F1"|Olympus<br />
|align = "right"| 212.89<br />
|align = "right"| 191.94 <br />
|align = "right"| 195.45 <br />
|-<br />
|bgcolor = "#DBE5F1"|FujiFilm HD<br />
|align = "right"| 26.98<br />
|align = "right"| 25.00 <br />
|align = "right"| 27.00<br />
|-<br />
|bgcolor = "#DBE5F1"|Hoya<br />
|align = "right"| 48.87 <br />
|align = "right"| 47.00 <br />
|align = "right"| 45.00 <br />
|-<br />
|}<br />
<br />
===Products Offered===<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Speciality'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Details'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Picture'''</font><br />
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Products'''</font><br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Gastroscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the interior of the stomach.<br />
|[[Image:Gastroscope2.PNG|120px]] [[Image:Gastroscope.PNG|120px]] [[Image:Gastroscope1.PNG|120px]]<br />
|<br />
* GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus<br />
* GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality<br />
* GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube<br />
* GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced. <br />
* GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.<br />
* GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view<br />
* GIF-2T160: Two-channel endoscope for a variety of therapeutic applications<br />
* GIF-XTQ160: Endoscope with powerful suction capabilities<br />
* GIF-1TQ160: Endoscope with extended instrumentation capabilities<br />
* GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Duodenoscopy''' <br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the duodenum<br />
|[[Image:TJF-Q180V.PNG|100px]] [[Image:TJF-160VR.PNG|100px]]<br />
|<br />
* TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function sets a new standard for ease-of-use and security during instrument exchange.<br />
* TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices<br />
* TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.<br />
* JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Colonoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the colon.<br />
|[[Image:CF-180AI.PNG|100px]] [[Image:CQ-180AI.PNG|100px]] [[Image:CF-Q160DI.PNG|100px]]<br />
|<br />
* CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.<br />
* CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.<br />
* PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics<br />
* CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.<br />
* CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.<br />
* CF-2T160I/L: Two-channel therapeutic capabilities<br />
* CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation. Powerful 150 times zoom magnification delivers detailed close-ups<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Proctoscopy'''<br />
|bgcolor = "#DBE5F1"| Endoscopic examination, therapy or surgery of the luminal surface of the rectum.<br />
|[[Image:Procto.PNG|100px]]<br />
|<br />
* Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.<br />
* Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard VISERA equipment.<br />
|-<br />
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Enteroscopy'''<br />
|bgcolor = "#DBE5F1"|Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach<br />
|[[Image:Enteroscope1.png|100px]] [[Image:Enteroscope2.png|100px]]<br />
|<br />
* QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel<br />
* Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel. <br />
* BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation<br />
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis<br />
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.<br />
|-<br />
|}<br />
<br><br />
Source: Company website<br />
<br />
===New Products===<br />
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.<br />
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.<br />
* '''Capsule Endoscopes:'''<br> [[Image:Capsule.png|right|120px]] They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy.<br> One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities.<br>The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach.<br>Product Details:[[Image:Capsule1.png|right|140px]]<br />
** Supersensitive CCD <br />
** Ultra compact lens <br />
** Automatic Brightness Control adjusts illumination to maintain optimal imaging <br />
** A wide depth of field provides superior observation <br />
** 6 white LED lights always ensure a clear field of view <br />
** Compact battery with energy efficient technology<br />
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.<br />
<br><br />
Source: Company website, SEC fillings</div>Venkata.reddy